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ABSTRACT 
 
 
STEPHEN LEE REGO.  Factors shed by breast tumor cells, tumor necrosis factor alpha 
converting enzyme activities, and the generation of pro-tumor macrophages.  (Under the 
direction of Dr. DIDIER DRÉAU) 
 
 
 The role of the tumor microenvironment, especially of tumor associated 
macrophages (TAMs), in the progression and metastatic spread of breast cancer is well 
established. TAMs are activated in the breast tumor microenvironment to express 
primarily a M2 (wound-healing) phenotype with minimal cytotoxic activities. The factors 
involved in the activation of TAMs to display a pro-tumor phenotype are still debated 
although the key roles of immunomodulatory cytokines released by tumor cells including 
colony stimulating factor 1 (CSF1), tumor necrosis factor (TNF) and soluble TNF 
receptors 1 / 2, soluble vascular cell adhesion molecule 1 (sVCAM1), soluble interleukin 
6 receptor (sIL6R) and amphiregulin (AREG) have been demonstrated. Notably, these 
factors are all released through the mechanism of ectodomain shedding by activities of 
tumor necrosis factor alpha converting enzyme (TACE, i.e., a disintegrin and 
metalloproteinase 17 (ADAM17)). The role of TACE activation leading to autocrine 
effects on tumor progression has been studied in detail. In contrast, limited information is 
available on the role of tumor cell TACE activities on TAM functions in breast cancer. 
TACE inhibitors, currently in development for clinical trials, may influence TAMs and 
subsequently treatment outcomes through the substrates TACE releases. However, the 
mechanisms altered in macrophages following exposure to tumor cell TACE-shed 
cytokines and/or cytokine receptors remain unclear. Therefore, we first outline (1) the 
current understanding of the roles of molecules released by TACE ectodomain shedding 
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from breast tumor cells on TAM phenotypes and functions. Next, we report (2) that 
tumor cell TACE activities specifically promote the shedding of TNFRs, which binds to 
and sequesters exogenous TNF, thereby preventing its pro-migratory effects on 
macrophages. These effects are shown to be mediated by the protein kinase B (AKT) 
signaling molecule, a common downstream target of TNFR2 but not of TNFR1. Further 
we detail (3) how tumor cell TACE-shed MCSF in combination with secreted chemokine 
(C-C motif) ligand 2 (CCL2) promote the secretion of vascular endothelial growth factor 
(VEGF) and subsequent angiogenesis. The pro-angiogenic abilities of these macrophages 
are shown to be dependent of nuclear factor kappa B (NFĸB) signaling. Finally, (4) these 
new data are summarized and discussed in the larger perspective of future research and 
treatments, harnessing the tumor stroma as a target in breast cancer. Overall, this research 
highlights specific mechanisms mediated by mammary tumor cell TACE-shed substrates 
involved in macrophage migration and promotion of angiogenesis that provide useful 
insights in the use of TACE inhibitors for the treatment of cancer as well as other 
potential targets involved in tumor cell modulation of TAMs. 
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CHAPTER 1: INTRODUCTION 
 
 
1.1 Clinical Relevance and General Features of Breast Cancer Progression 
Breast cancer is the most common malignancy among women in developed 
countries accounting for a third of total cancers diagnosed in women [1]. The American 
Cancer Society estimates more than 230,000 new breast cancer cases will be detected and 
that nearly 40,000 breast cancer related deaths will occur in the United States in 2013 [2]. 
Most cancer related mortalities are associated with complications due to metastasis, i.e., 
the spread of cancer. An estimated 1 out of 3 women with breast cancer will develop 
metastases [1,2]. Treatments for primary breast tumors have greatly improved and the 
recurrence of primary early breast cancer at least in the 5-year following diagnosis can be 
prevented in most patients through combinations of surgery, chemotherapy, and radiation 
[3]. In contrast, treatments for patients with metastatic breast cancer remain overall 
ineffective. Although our understanding of breast cancer progression and metastasis 
including the numerous molecules and mechanisms involved continues to improve, 
detailed knowledge of the origin, concentration and interplay of these molecules within 
the breast cancer microenvironment is still lacking. Indeed, the identification of these 
interactions during breast cancer progression will provide additional therapeutic targets 
for disease treatment while limiting potential side effects. 
The progression from a benign state to a malignant state is associated with the 
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acquisition by tumor cells of multiple characteristics including (1) the ability to promote 
uncontrolled growth irrespective of the microenvironment, (2) loss of dependence on 
growth signals essential to the proliferation of normal cells, (3) insensitivity to anti-
growth signals, (4) ability to evade programmed cell death or apoptosis (5), induction of 
angiogenesis, and (6) activation of metastasis (Figure 1.1) [4].  
More recently, two emerging hallmarks of cancer were added: chronic 
inflammation associated with abundant inflammatory cells, cytokines and gaseous 
mediators and the capacity to evade immune detection (Figure 1.2) [5]. Overall, within a 
tumor mass, the net growth is directly proportional to the ratio tumor cell proliferation 
and tumor cell apoptosis. These characteristics are acquired through both tumor intrinsic 
as well as extrinsic mechanisms mediated by genomic alterations in the tumor cells and 
alterations of the microenvironment, respectively. 
Intrinsic mechanisms used by tumor cells to evade anti-proliferative and pro-
apoptotic extracellular signals have been demonstrated in breast cancer cells [6]. For 
example, activating mutations leading to constitutive activation of epidermal growth 
factor receptor (EGFR) or the Ras family of proteins, commonly observed in cancers, 
promote uncontrolled tumor cell proliferation. Additionally, cancer cells often acquire 
inactivating mutations in pro-apoptotic genes such as B-cell lymphoma 2 (bcl-2) and the 
first discovered human tumor suppressor gene retinoblastoma (Rb). Furthermore, both the 
shedding of growth factors, transforming growth factor alpha (TGFα) and AREG, and 
death receptors, TNFR1, have been shown to activate autocrine growth factor signaling 
and inhibit apoptotic signaling, respectively [6,7]. These mechanisms are well defined 
and widely studied as driving forces in tumorigenesis. However, although required, these 
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intrinsic mechanisms are not sufficient for a tumor cell to become fully invasive [4,5]. 
Indeed, aside from tumor cell mutations, evidence of the involvement of the tumor 
microenvironment in promoting breast cancer progression (described below) is 
accumulating [8,5,9]. 
1.2 The Tumor Microenvironment 
In addition to a dense network of proteins forming the extracellular matrix 
(ECM), the tumor microenvironment consists of different stromal cells, including 
endothelial cells (ECs), fibroblasts, adipocytes, and infiltrating immune cells [8,10] 
(Figure 1.2). The infiltrating immune cells comprise leukocytes, T-cells, and monocytes 
[8,11,12]. The phenotype of these immune cells is influenced by the tumor 
microenvironment leading to the recruitment and generation of both T regulatory cells 
(Tregs) and tumor associated macrophages (TAMs) [13-15]. In a subset of breast cancers, 
the inflammatory breast cancers (IBC) tumor masses are infiltrated by a large number of 
immune cells: in some cases, more than 50% of the tumor mass consists of macrophages 
[16]. This infiltration and activation of these macrophages contributes to the 
inflammatory environment associated with this aggressive form of breast cancer as well 
as the other subtypes of breast cancers [14,17]. 
The reciprocal interactions, mediated by soluble factors, between tumor cells and 
the surrounding stroma, especially immune cells, can lead to amplified pro-tumor effects 
in a tumor mass [18]. Indeed, tumor cells have been shown to influence the surrounding 
microenvironment through multiple mechanisms [5]. For example, tumor cells release 
chemotactic molecules, including macrophage colony stimulating factor (MCSF) and 
chemokine (C-C motif) ligand 2 (CCL2), which attract specific subsets of immune cells 
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to the tumor site, including macrophages [19-21]. In addition, tumor and immune cells 
secrete specific cytokines, growth factors (GFs), reactive oxygen species (ROS), and 
hydrolytic enzymes, all paracrine and autocrine modulators of the local immune response 
and tumor behavior [8,19,5,9]. Tumor cells have also been shown to shed surface 
receptors, through the activity of specific enzymes such as A Dis-integrin Metallo-
proteinases (ADAMs), leading to inhibition of anti-tumor cytokine activities [6].  
The interactions between stroma and tumor cells, mediated by soluble factors, are 
the subjects of intense research especially toward fully understanding the potential to 
alter the tumor stroma in preventing breast cancer progression [5,22]. Cytokines [e.g., 
interleukin 6 (IL-6), transforming growth factor β (TGFβ)], chemokines [e.g., Chemokine 
(C-X-C motif) ligand 8 (CXCL8), CXCL12, CCL2, CCL5], and other mediators such as 
prostaglandins and reactive oxygen species (ROS) have already been identified as 
molecules involved in the tumor cell / immune cell interactions [23-27].  
TNF, primarily released by macrophages, is a key cytokine in inflammation with 
pleiotropic effects including control of cell proliferation, differentiation, and apoptosis in 
numerous cells [28]. Because of its key role in inflammation, TNF blocking treatments 
have been investigated and are used to treat rheumatoid arthritis [29]. However, the 
effectiveness of TNF-based treatments in cancer have been limited and hindered by 
significant side-effects [30]. Nevertheless, TNF-based treatments specifically targeting 
tumors led to tumor cell death and decreased vascularization [30].  
Taken together, these observations strongly support a key role for tumor derived 
soluble factors in generating a microenvironment permissive to cancer progression and 
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the crucial importance of this tumor microenvironment in promoting cancer progression 
and metastasis. 
1.3 Inflammation 
More than 150 years ago, Dr. Rudolph Virchow observed that malignancies were 
accompanied by increased levels of immune cell infiltrate and postulated that cancer 
arose in sites of inflammation [31]. Data collected over the past decades further support 
for the role of inflammation in cancer [32-34,5,17]. Indeed, recently the inflammatory 
environment of the adipose tissue was linked to cancer initiation and progression [35]. 
Overall, while an acute inflammatory response may hinder cancer initiation, chronic 
inflammation leads to the development and progression of established breast cancer [31].  
Although inflammatory breast cancer represents only 5% of the total of breast cancer 
cases it is one of the most aggressive forms [36]. Indeed, inflammation of the breast 
tumor is an indicator of poor prognosis [36]. The pro-tumor effects of chronic 
inflammation are mediated by inflammatory cytokines (Table 1), secreted by the tumor 
and the stromal cells present in the tumor microenvironment [37]. Macrophages have 
prominent roles in both the initiation and persistence of an inflammatory response [33]. 
Initiated by damage or stress signals, the onset of inflammation promotes the 
recruitment and infiltration of macrophages from adjacent tissue and/or the bone marrow 
[33,37]. Within the tumor mass, macrophages generate a sustained inflammatory 
microenvironment, which in turn secrete various cytokines, including TNF and CCL2 to 
further the recruitment of additional inflammatory cells. The signals present in the 
microenvironment influence the macrophage phenotype to sustain a classically activated 
inflammatory (M1) phenotype or an anti-inflammatory (M2) phenotype or any variation 
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in between. The M2 macrophages have been shown to function as immuno-suppressive 
cells [38]. The M1 and M2 phenotypes lie at the extremes of a continuum of macrophage 
activation states [39]. Interestingly, a mixed population of macrophages containing 
characteristics of both M1 and M2 macrophages were found in the adipose tissue 
adjacent to a growing tumor [35]. Typically, M2 macrophages are thought to be pro-
tumor whereas M1 have anti-tumor properties [38]. However, inflammatory M1 activated 
macrophages have important roles in tumor initiation through release of ROS whereas 
later during tumor progression M2 macrophages are shown to promote invasion of tumor 
cells through the ECM towards nearby blood vessels [9,35,40]. These data and other 
[41,14,42,43] underline that pro-tumor functions shown in both macrophage phenotypes 
depends on their temporal/spatial localization, suggesting that the M1/M2 classification, 
although useful, may not be completely relevant to describe the tumor associated 
macrophages. Regardless of their phenotype, macrophages play a critical role in the 
promotion and maintenance of the vasculature and are extremely important in promoting 
the formation of new blood vessels or angiogenesis. 
1.4 Angiogenesis 
As tumors grow, cancer cells within the tumor mass further away from the blood 
vessels are oxygen and nutrient deprived leading to the accumulation of spent molecules 
during the early phase of this highly metabolic process [44]. Low oxygen concentration 
(pO2) or hypoxia due to poor diffusion and distance from blood vessels affects cells in the 
center of a tumor mass as little as 250-1000 cells [44]. Intracellular hypoxia triggers a 
cascade of intracellular responses including the stabilization of hypoxia inducible factor 1 
α (HIF1α) and its combination with the constitutively expressed HIF1ß forming a 
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transcription factor that promote the expression of multiple molecules promoting 
angiogenesis including, VEGF [45,46] (Figure 1.3). Angiogenesis promotes tumor 
progression toward a malignant state. The “angiogenic switch” defines the change of 
endothelial cells from dormant to rapidly growing resulting in the development of a dense 
microvasculature that connects to the host circulation to the tumor mass and is thought to 
be controlled by macrophages in many settings including cancer [41]. In contrast with 
normal vasculature, this newly formed tumor vasculature is much less organized and 
lacks most pericytes [47]. In addition to alterations in HIF1α expression, preclinical and 
clinical observations indicate that molecules expressed by tumor infiltrating immune cells 
especially macrophages also activate tumor angiogenesis [41]. For example, inhibition of 
macrophage maturation led to a decrease in angiogenesis, whereas the presence of high 
number of macrophages within the tumor mass in transgenic mouse models caused 
increased tumor vasculature and subsequent malignant progression [41].  
Specifically, inflammatory molecules secreted by macrophages including VEGF 
and matrix metalloproteinase (MMPs) are both promoters of angiogenesis [41,48,49]. 
VEGF is a potent angiogenic factor released by both tumor cells and macrophages and 
receptors stimulated by VEGF (VEGFRs) have been successfully targeted in many 
cancers [45,46]. Targeting VEGFRs for the treatment of breast cancer has been 
ineffective [50], indicating the need to gain a fuller understanding of the molecules and 
mechanisms in breast cancer angiogenesis to provide further targets for inhibiting this 
pathway. The multiple interactions between tumor cells and macrophages associated 
macrophages leading to the promotion of angiogenesis and cancer progression remain to 
be fully assessed. 
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1.5 Modeling Cell-Cell Interactions to Study Cancer 
The complexities of the tumor microenvironment in vivo render analyses of 
specific cell signaling and molecular interactions challenging [51,40]. Therefore, multiple 
approaches, especially in vitro, have been developed [52,51,10,53]. To study the effects 
of hypoxia within a growing tumor mass 3D modeling systems with tumor spheroids / 
colonies have been developed which possess a characteristic necrotic core due to 
decreased oxygen / nutrient diffusion [54,10]. Numerous co-culture systems have been 
engineered to study the effects of one cell type on another including direct, transwell and 
conditioned media (CM). For the study of interactions mediated by direct cell-cell effects 
the use of the direct co-culture method is appropriate [55,56]. This system has led to the 
discovery of many adhesive interactions of tumor cells and macrophages mediated by 
integrins as well as providing a simplified way to observe the process of tumor cell-
macrophage co-invasion observed in the process of tumor cell streaming [40]. To analyze 
the reciprocal crosstalks between tumor cells and macrophages mediated by soluble 
factors the transwell co-culture systems are suitable and have been used in many studies 
revealing the soluble factors involved in TAM promotion of tumor cell migration, 
invasion and streaming [40,57]. Finally, to analyze the effects of one cell type on another 
the use of CM provides simplified and fitting approach. This method minimizes the 
complexities of multiple cell co-culture systems, allows one to have improved control 
over culture conditions and makes the effector cell type easier to identify [53,26,58,59]. 
Furthermore, this system allows the specific targeting of factors only on one cell type 
whereas other co-culture methods make this task much more challenging.  In the studies 
performed here CM was used to make many of the observations, providing a useful way 
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to isolate the effects of specific tumor associated environmental factors on macrophage 
phenotype in vitro and gain a clearer understanding of the mechanisms and pathways 
involved in these interactions. 
1.6 Tumor Cell TACE Shedding in Stimulating Pro-tumor TAMs 
The tumor derived soluble factors associated with pro-tumor activities and 
involved in the modulation of macrophages include MCSF, TNF and TNFRs [38]. These 
factors are released from cells through ectodomain shedding by the enzyme TACE [60]. 
Levels of TACE and the TACE substrate TGFα are correlated to decreased survival in 
breast cancer patients [7]. One mechanism to explain this observation was shown through 
TACE shedding of EGFR ligands stimulated autocrine activation of EGFR and 
downstream growth factor signaling pathways in breast cancer cells [7]. 
To date, no studies have investigated the paracrine roles of tumor cell TACE 
shedding on stromal cells within the breast tumor microenvironment. Based on the 
immune-modulatory factors shed by TACE, including MCSF, TNF and TNFRs, TACE 
activities may significantly modulates the behavior of various stromal cells within the 
breast tissue, especially macrophages. Both TNF and MCSF have positive effects on 
macrophage migration, however, these two molecules lead to opposite effects on 
macrophage polarization [38]. Indeed, TNF promotes the activation of M1 cytotoxic 
macrophages whereas MCSF stimulates M2 wound-healing macrophages [38]. Whether 
tumor cell TACE shedding influences pro-tumor macrophage activities is still unknown 
(outlined in Figure 1.4). 
1.7 Objectives 
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Therefore, here we first outlined the known pro-tumor activities of TACE 
substrates in mammary tumorigenesis and the effects of TACE substrates on macrophage 
functions through an extensive literature review (Chapter 2). Next, we demonstrated the 
effects of tumor shed TNFRs on the migration of macrophages towards TNF (Chapter 3). 
In Chapter 4, we investigated the role of tumor cell TACE-shed MCSF in promoting pro-
angiogenic macrophages. Since, in breast cancer, MCSF alone has not been implicated in 
stimulating TAM angiogenesis we determined whether other factors, such as CCL2, were 
involved in promoting angiogenic macrophages. Finally, the importance of these 
findings, in furthering our understanding of tumor associated macrophages and shaping 
the future of breast cancer treatments, is discussed. 
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Table 1.1. Cytokines involved in breast cancer [61]. The effects of numerous cytokines 
on tumor growth and invasion in human patients are outlined. Many of these cytokines 
are shown to have an impact on the prognosis of patients. 
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Figure 1.1. The hallmarks of cancer [5] outlines six critical characteristics needed for a 
cell to become malignant including sustained proliferation, decreased apoptosis, 
inhibition of growth suppression, angiogenesis, decreased senescence and implementing 
metastasis. All of these characteristics are required for a tumor to become malignant. 
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Figure 1.2. Recent additions to the hallmarks of cancer [5]. Along with the six 
characteristics of cancer cells described previously, studies over the last ten years reveal 
four more properties of malignant cells including unregulated metabolism, genome 
instability, evade immune detection and inflammation. 
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Figure 1.3. Linking hypoxia to angiogenesis through tumor cells and macrophages [62]. 
Critical properties of the tumor microenvironment, hypoxia and inflammation, are shown 
to exert tumor promoting effects on one another such that these conditions promote the 
invasion of tumor cells towards the vasculature. 
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Figure 1.4. Proposed effects of tumor cell TACE shedding of substrates on various tumor 
associated macrophage functions. The studies presented investigate the paracrine effects 
of TACE shedding by tumor cells on macrophage migration, angiogenesis and matrix 
remodeling. The detailed pathways involved in these interactions are critical to the 
understanding of tumor cell interactions with their microenvironment. These studies 
utilize different in vitro approaches including conditioned media, transwell migration and 
endothelial cell tube formation assays. 
 
 
 
CHAPTER 2: TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME 
ACTIVITES AND TUMOR-ASSOCIATED MACROPHAGES IN BRESAT 
CANCER 
 
 
2.1 Abstract 
The role of the tumor microenvironment especially of TAMs in the progression 
and metastatic spread of breast cancer is well established. TAMs have primarily a M2 
(wound-healing) phenotype with minimal cytotoxic activities. The mechanisms by which 
tumor cells influence TAMs to display a pro-tumor phenotype are still debated although 
the key roles of immuno-modulatory cytokines released by tumor cells including CSF1, 
TNF and sTNFR1 / 2, sVCAM1, sIL6R and AREG have been demonstrated. Importantly, 
these factors are released through ectodomain shedding by the activities of the TACE. 
The role of TACE activation leading to autocrine effects on tumor progression has been 
extensively studied. In contrast, limited information is available on the role of tumor cell 
TACE activities on TAMs in breast cancer. TACE inhibitors, currently in clinical trials, 
will certainly affect TAMs and subsequently treatment outcomes based on the substrates 
it releases. Furthermore, whether targeting a subset of the molecules shed by TACE, 
specifically those leading to TAMs with altered functions and phenotype, hold greater 
therapeutic promises than past clinical trials of TACE antagonists remain to be 
determined. Here, the potential roles of TACE ectodomain shedding in the breast tumor 
microenvironment is reviewed with a focus on the release of tumor-derived immuno-
modulatory factors shed by TACE that direct TAM phenotypes and functions.
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2.2 Pro-tumor Functions of TAMs Modulated by TACE 
In addition to their intrinsic properties, breast tumor cell growth and ability to 
form metastases rely heavily on interactions with stromal cells in the breast tumor 
microenvironment [5,63]. Indeed, within the breast tumor microenvironment structural 
proteins from the ECM and both soluble and insoluble factors generated by tumor cells 
and stroma cells including immune cells, fibroblasts, endothelial cells and adipocytes 
modulate cancer progression. Although each of these stroma cells influences breast 
cancer progression, TAMs in particular have been associated with worsened clinical 
outcome in breast cancer patients [64,65].  
Macrophages located in and around the tumor i.e., the TAMs have both anti- and 
pro-tumor activities [66,20,67-69] which have been detailed thoroughly in breast cancer 
[64,8,70-73,20,57]. TAMs display diverse functions and lie on a phenotype continuum 
from M1 macrophages with anti-tumor properties (classically activated) to M2 
macrophages with pro-tumor properties (alternatively activated) [74]. It should be 
emphasized that this classification system was developed to highlight the markers and 
functions of M1 and M2 macrophages in different contexts and may not precisely 
represent the anti-tumor and pro-tumor TAMs, respectively. Indeed, other distinct 
populations of monocyte-derived cells isolated within the breast tumor microenvironment 
have been identified including the Tie2 expressing monocytes (TEM) [17]. Furthermore, 
macrophages expressing the canonical M1 marker inducible nitric oxide synthase (iNOS) 
had anti- and pro-tumor effects on the cytotoxicity and tumor cell invasion, respectively 
[73]. Nonetheless, the M1 / M2 nomenclature system provides a useful framework to 
group functionally distinct macrophage subsets in cancer. 
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Macrophages express distinct phenotypes based on signaling molecules present in 
their local microenvironment [74]. This macrophage plasticity will vary depending on 
cytokine exposure, ECM composition and oxygen availability [74,38]. In the breast 
tumor microenvironment, the pro-tumor activities of TAMs are modulated by numerous 
tumor derived soluble factors (TDSFs). Many TDSFs are released from tumor cells by 
ectodomain shedding mediated mainly by the sheddase TACE; i.e., ADAM17 [75,76]. 
TACE-shed TDSFs essential in the recruitment and activation of pro-tumor TAMs 
include; CSF1, TNF, intercellular adhesion molecule 1 (ICAM1), vascular cell adhesion 
molecule (VCAM1), sIL6R, AREG and TGFα [7,77,66]. 
In the present review, we detail the mechanisms associated with the TACE 
shedding by tumor cells within the tumor microenvironment focusing on its effects on 
macrophage activity and tumor progression and briefly summarize the well-defined pro-
tumor effects of TACE activities. Additionally, the role of TACE in paracrine cell 
signaling involved in normal mammary tissue homeostasis is addressed. The activities of 
TACE in epithelial cell-stromal cell interactions during normal mammary gland 
development and breast cancer have been studied and will be discussed here. Further, 
these interactions are relevant to the growth of any tumor mass in which TACE-shed 
factors and macrophages are present, however, few studies investigate this process 
outside of the mammary gland. Here, the impact of tumor cell TACE-shed factors in the 
promotion of pro-tumor macrophages and in the compartmentalization of specific 
macrophage subsets to distinct areas of the tumor is discussed. The main thrust of the 
present review is to define the influential role of TACE directed ectodomain shedding by 
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tumor cells on TAMs recruitment and phenotype. Other TACE activities have been 
reviewed elsewhere recently [78,75,79,80]. 
2.3 TAMs Phenotype and Function in Breast Cancer 
TAMs exert pro-tumor effects through the promotion of angiogenesis, 
degradation of the ECM, suppression of antitumor immune responses and promotion of 
tumor cell invasion [81,13,20,9,42,82]. In many cancers, including breast cancer, the 
increased presence of TAMs is associated with increased aggressiveness of tumors and 
decreased patient’s survival [17,20,83,63,84]. Furthermore, numerous studies suggest the 
pro-tumor activities of TAMs prevail in breast cancer [81,85,20,83,66]. However, the 
mechanisms by which the TAMs are skewed toward a pro-tumor (M2) phenotype remain 
unclear. TAMs are recruited to the tumor site from the bone marrow in response to 
signals released by both tumor and stromal cells [20,83,66]. The steps of macrophage 
trafficking to the tumor site include monocyte production in the bone marrow and 
transport within the blood stream, adhesion to the endothelium, diapedesis and invasion 
[86]. This process is guided by the presence of chemotactic and chemostatic molecules 
leading to the mobilization of macrophages in different regions of the breast tumor 
[17,20,86]. Interestingly, macrophages with different phenotypes i.e., different 
membrane-bound and excreted protein profiles, are located in distinct areas of a tumor 
[42,74]. Indeed, the immature population of monocytes (TEM) localize to the hypoxic 
core [17], whereas M2-like macrophage populations are found at the invasive edge of 
breast tumors [85]. The pathways activated in macrophages and molecules released by 
the tumor stroma leading to the generation of macrophage subsets in distinct tumor 
regions are under intense investigation [74,23,22,87,14,9,42]. 
20 
2.4 Pro-Tumor Activities of TACE 
Tumor cells release many pro-tumor factors that promote tumor cell growth and 
alter macrophage phenotype and migration in the microenvironment [39,20,57,88,70], 
including AREG, TGFα, CSF1, TNF, VCAM1, sIL6R, and ICAM1 respectively 
[7,77,66]. These molecules are released from tumor cells through ectodomain shedding 
by TACE [78,7,77]. This sheddase belongs to the ADAM family of transmembrane 
proteins, and structurally includes a metalloprotease domain, an integrin binding domain, 
and a cytoplasmic tail [78-80]. In addition to protein shedding, ADAMs are involved in 
integrin binding and intracellular signaling through their disintegrin and cytoplasmic 
domains, respectively [75,60]. During ectodomain shedding, proteins are proteolytically 
cleaved from the cell membrane. This process frees approximately 10% of all proteins 
released from cells into the extracellular space [89]. 
In vitro the pro-tumor activities of TACE include increases in tumor growth, 
proliferation, invasion, and maintenance of the malignant phenotype of tumor cells [7,90-
93]. In vivo TACE activities also promote tumor growth, tumor formation and tissue 
invasion [90]. Additionally, increased protein expressions of TACE have been correlated 
to clinical parameters of tumor progression i.e., presence of lymph node metastases and 
decreased patient’s overall survival [7,91]. Specifically, TACE pro-tumor activities 
initiate the shedding from breast tumor cells of the epidermal growth factor receptor 
(EGFR) ligands, TGFα and AREG, which through autocrine signaling promote the 
malignant phenotype [7,93]. Over expression of TACE and one of its substrates TGFα 
also correlated with decreased survival in breast cancer patients [7,94]. These 
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observations support the use of TACE as a therapeutic target for the treatment of breast 
cancer. 
2.5 Inhibition of TACE 
TACE inhibitors have been investigated as a means to prevent / limit 
inflammation by blocking the release of TNF in inflammatory diseases [78]. In past phase 
2 clinical trials, the TACE inhibitors tested (TMI-005 and BMS-561392) were 
unsuccessful due to their lack of efficacy and systemic toxicities [78]. Both of these 
inhibitors displayed off-target inhibition of MMPs, including MMP1, MMP2 and 
MMP13, which may account for their observed liver toxicities [95]. However, more 
specific TACE inhibitors may be associated with limited liver toxicities. Indeed, a 10-
fold reduction in liver toxicities was observed in mice treated with specific TACE 
inhibitors compared to those administered BMS-561392 [96]. Currently, TACE more 
specific inhibitors, which have shown great promise in anti-inflammatory preclinical 
studies, are under investigation [78]. These trials highlight the potentials and the 
challenges associated with the use of TACE inhibitors in treating breast cancer patients. 
In particular, they highlight the need for an in-depth understanding of the indirect effects 
of TACE and TACE inhibitors on stroma cells, specifically macrophages, as a key step 
toward the successful use of TACE inhibitors to treat breast cancer patients. 
2.6 Expression and activities of TACE during normal breast tissue development 
2.9.1 TACE Expression and Activities 
The primary function of TACE is ectodomain shedding leading to the release of 
trans-membrane proteins from the cell surface (outlined in Figure 2.1). The ectodomain 
shedding resulting from TACE activities releases functional ligands including cytokines 
22 
and growth factors, which upon binding to their cognate receptors activate autocrine and / 
or paracrine signaling pathways [60]. TACE activities can also shed receptor-like 
molecules from the cell membrane, which once freed can sequester associated ligands 
within the microenvironment thereby preventing their signaling effects on cells [60]. In 
breast tissues, TACE sheds multiple growth factors and cytokines with essential roles in 
both normal mammary gland development and immune cell functions [97,98]. Indeed, 
the experimental deregulation of TACE activities, required for normal development, 
maintenance and function of the breast tissue, promotes breast tumorigenesis (Table 1) 
[60,7,97]. TACE is expressed in nearly all cell types with, however, variable expression 
and activity levels [76,99,100]. The expression and activities of TACE by various cells, 
including macrophages and chondrocytes, [101,102,60,103,104] endothelial and vascular 
smooth muscle cells [105,56], and astrocytes [106]  have been reviewed earlier 
[56,60,101,105,106]. Human tissues with highest TACE expression include the heart and 
reproductive organs and cell types with relatively high expression levels include 
macrophages as measured by Western and Northern blot analysis [76,60]. 
2.9.2 TACE in Mammary Development 
Normal mammary gland development occurs mainly during puberty and toward 
the end of pregnancy and includes steps of branching morphogenesis leading to complex 
ductal networks [107,108]. This process is tightly regulated in part through reciprocal 
cross-talks between epithelial and stromal cells [97,98]. Using tissue recombination 
methods with wild type and transgenic mice, Sternilicht et al. showed that the expression 
of TACE and AREG on epithelial cells and the expression of EGFR on stromal cells are 
required for normal mammary ductal morphogenesis [98]. In particular, TACE cleavage 
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of AREG from epithelial cells, allowed AREG to bind to and activate EGFR on stromal 
cells, thereby promoting ductal growth [97,98]. TACE activation also specifically affects 
stromal macrophages in mammary gland development, leading to activities that are 
critical to branching morphogenesis through mediating the formation of terminal end 
buds [109,110]. 
2.7 Expression and Activities of TACE During Cancer Progression 
Microenvironmental signals modulate the activation status of each cell type 
within the tumor mass including the expression and activities of TACE. Indeed, increased 
TACE gene / protein expression is observed in both macrophages during inflammation 
and macrophages isolated from patients with triple negative breast cancer [102,111]. The 
TACE activities of macrophage at sites of inflammation lead to the release of several 
inflammatory cytokines, including TNF, a critical pleotropic cytokine involved in cell 
death, cell migration and inflammation [60,109,78,77,112]. Details on the importance of 
macrophage TACE activity and its consequences on the inflammatory process can be 
found in recent reviews [112,109,78]. 
Along with the role of TACE in normal mammary gland development and 
inflammation activities of TACE are pivotal in breast tumorigenesis and metastasis as 
demonstrated by observations that the experimental upregulation of TACE in mammary 
tissue promotes malignancy (Table 1) [60,7,97]. Increased TACE shedding led to the 
release and binding of EGFR ligands, AREG and TGFα to EGF receptor(s) on the breast 
cancer cells sustaining the malignant phenotype of breast tumors. Also, the activation of 
the EGFR on breast cancer cells led to the activation of the mitogen-activated protein 
kinase (MAPK) pathway which stimulated cancer cell proliferation and a loss of cell 
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polarity in 3D in vitro cultures [7]. In this study, both chemical inhibition of the TACE 
metalloproteinase activity and knockdown with TACE siRNA prevented the expression 
of the malignant phenotype [7]. This is one critical mechanism employed by tumor cells 
to decrease their reliance on external growth factors and an essential early step in 
tumorigenesis. Similar mechanisms have been demonstrated in colorectal cancer leading 
to increased resistance to chemotherapies [113]. 
TACE cleaves many EGFR ligands including AREG and TGFα as well as heparin 
binding EGF (HB-EGF) and epiregulin (EPR) [7,97,114]. The ErbB family of receptors 
has been implicated in breast cancer progression in particular through the ErbB1 / EGFR 
signaling pathway [115,7]. Indeed, the deregulation of EGFR contributes to the decreased 
reliance of tumor cells on external growth signals, a defining characteristic of 
tumorigenesis [7]. Growth factor receptor pathways are vulnerable to malignant 
transformations including mutations to the receptor or to downstream signaling molecules 
resulting in a constitutive activation [116]. Alternatively, continuous release of ligands 
stimulating autocrine signaling also disrupt the tumor cells EGFR pathway [7]. TACE 
shedding and the autocrine effects of EGFR ligands in breast cancer have been well 
studied [78,117,80]. 
2.8 The Effects of TACE Substrates on Macrophages in Cancer 
In contrast with the extensively studied autocrine effects of tumor TACE 
shedding [78,117,80], data on the effects of tumor cell TACE shed factors on TAMs are 
limited. The TACE substrates involved in the tumor cell / macrophage interactions 
include CSF1, TNF and TNFRs, ICAM1, VCAM and EGFR ligands. Each of these 
molecules modulates one or more steps of macrophage recruitment and / or phenotype 
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activation. Thus, these TACE-shed molecules participate in the formation of specific 
macrophages along the M1 - M2 continuum in the breast tissue. Furthermore, TNF and 
EGFR ligands also dramatically affect the survival of macrophages once in the target 
tissue.  
The primary effects of TACE-shed molecules on macrophages are presented in 
Table 2. The substrates of TACE involved in regulating macrophage activities include 
CSF1, CSF receptor 1 (CSFR1), TNF, TNFR1/2, TGFα, AREG, interleukin 1Rα (IL-
1Rα), mucin 1 (MUC1), VCAM1, ICAM1, sIL6R, L-selectin (CD62L), lymphocyte 
activation gene 3 (LAG-3), CD30, CD40, IL-6R, chemokines (CX3CL1 and CXCL16), 
junctional adhesion molecules A (JAM-A), and the MHC class I polypeptide-related 
sequence A (MICA) [28,74,70,78,20,38,39,86,118,117]. Of these molecules CSF1, TNF, 
TNFRs, VCAM1 and ICAM1 are released by tumor cells and critically regulate pro-
tumor macrophage phenotype and functions. 
2.9.1 Tumor Cell TACE-shed CSF1 and TAMs 
CSF1, TNF, TNFRs, VCAM1 and ICAM1 play essential role in the interactions 
of breast cancer cells and macrophages as they promote changes in macrophage 
phenotype, migration and apoptosis. The presence and binding of CSF1, shed by breast 
tumor cells through TACE activities, to CSFR1 highly expressed by macrophages within 
the tumor mass correlates with poor prognosis [119]. In a CSF1 null transgenic mouse 
model that spontaneously developed mammary tumors, the presence of the CSF1 protein 
was shown to significantly increase the number of lung metastasis while having no effect 
on primary tumor growth [20]. More recently, a paracrine feedback loop between tumor 
cells secreting CSF1 to recruit and activate TAMs and TAMs stimulating production of 
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EGF, which in turn promotes the invasion of tumor cells, was identified using an in vivo 
murine model [57,71]. This feedback loop is also essential in directing tumor cell / 
macrophage streaming to the tumor microenvironment of metastasis (TMEM) leading to 
dissemination of tumor cells from the primary tumor into the circulation. Others have 
shown a similar mechanism of tumor derived CSF1 stimulating TAMs to produce stromal 
cell-derived factor 1 (SDF1) and VEGF leading to increased angiogenesis and tumor cell 
invasion [19]. Additional research is required to define whether the breast tumor / 
macrophage feedback loop directed by CSF1 primarily stimulates the production of EGF 
or other molecules such as SDF1 and VEGF to determine the relative role of each of 
those factors in tumor progression.  
CSF1 activation of CSF1R on macrophages has been shown to alter every aspect 
of macrophage functions including proliferation / survival, differentiation and migration 
through stimulation of the phosphatidylinositide 3-kinases / rat sarcoma (PI3K/Ras), 
Phospholipase Cγ2 / PI3K (PLCγ2/PI3K) and sarcoma / PI3K (Src/PI3K) pathways, 
respectively [120]. Additionally, macrophages stimulated by CSF1 support the promotion 
and maintenance of angiogenesis in mammary tumors [41]. Moreover, our recent data 
indicates that macrophages stimulated by tumor cell TACE-shed CSF1 secrete higher 
levels of the angiogenic factor VEGF [121]. Furthermore, knocking down the expression 
of CSF1 by breast tumor cells prevented both the colonization and activation of TAMs at 
the tumor site and also significantly limited the ability of tumor cells to form metastases 
[20]. These observations strongly support the involvement of CSF1-activated TAMs in 
breast cancer promotion and metastasis [122,57,71]. 
2.9.2 Tumor Cell TACE-Shed TNF / TNFRs and Macrophages 
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The pleiotropic cytokine TNF is also a key substrate of TACE critical in the 
promotion of inflammatory responses. Both stroma cells and macrophages release TNF to 
promote inflammation, which can either lead to apoptosis of tumor cells or tumor 
promotion [123-126]. TNF promotes the chemotaxis of macrophages to sites of 
inflammation, where additional TNF activation stimulates macrophages toward the 
classically activated phenotype [38,127]. The receptors for TNF (TNFR1 and TNFR2) 
are expressed by most cells of the body and are also susceptible to ectodomain shedding 
[124,128,129]. Once shed by TACE sTNFRs, bind to TNF, thereby blocking its signaling 
effects including apoptosis of tumor cells and chemotaxis and activation of macrophages 
[124]. Indeed, sTNFRs shed by tumor cells through TACE activities inhibited 
macrophage activation of AKT and subsequent chemotaxis toward TNF [130]. As with 
EGF and EGFR shedding, tumor cells may use TNF - sTNFR interactions to modulate 
the number and phenotype of macrophages within the tumor or specific tumor locations. 
2.9.3 TACE Shed VCAM1 / ICAM1 and TAMs 
Serum levels of the adhesion molecules and TACE substrates, sVCAM1 and 
sICAM1, have been correlated with breast cancer staging [131] and metastasis [132-134], 
respectively. Further, sVCAM1 serum concentrations correlated with microvasculature 
density in tumors, the presence of circulating tumor cells (CTLs) [135,131] and decreased 
tumor cell killing [70]. VCAM1 expression by breast tumor cells has been shown to 
promote metastasis to the lungs [136,70,131]. Mechanistically, VCAM1 on tumor cells 
interacts with integrins on macrophages leading to tumor cell survival and invasion 
through PI3K signaling [70]. Moreover, through these interactions and in conjunction 
with macrophages, breast tumor cells metastasize to the bone [137]. Since VCAM1 is 
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also involved in the accumulation of monocytes at atherosclerotic lesions, VCAM1 also 
likely plays an essential role in generation of the metastatic niches for breast tumor cells 
[138]. 
ICAM1 correlates to TAM abundance and is involved in macrophage infiltration 
to the tumor site [139-141]. Furthermore, ICAM1 mediates tumor cell / macrophage 
adhesion through heterotypic binding to MUC1 [139,142]. Macrophage adhesion to the 
endothelium is also mediated in part through interactions with ICAM1 further indicating 
the role of ICAM1 in macrophage infiltration into the tumor site [143]. ICAM1, through 
interactions with other selectins / integrins supports the adhesion of tumor cells to the 
endothelium during the metastatic process [134,144,145]. Interestingly, macrophages 
play an essential role in the adhesion of tumor cells to the endothelium and extravasation 
during the process of metastasis through interactions with ICAM1 as well [146,140,147]. 
Furthermore, our recent data that indicates molecules shed through TACE activities, 
which includes ICAM1, by tumor cells differentially regulate macrophage subset 
chemotaxis, having stronger effects on M2 macrophages while minimally affecting M1s 
[148]. Altogether, the shedding by tumor cells of CSF1, TNF, TNFRs, VCAM1 and 
ICAM1 through TACE activities greatly impacts tumor cell progression and metastasis in 
part through the modulation of tumor cell / macrophage interactions at both primary and 
metastatic sites. 
2.9.4 TACE-Shed IL6R and IL6 Trans-signaling and TAMs 
 Canonical IL6 signaling is engaged in cancer progression. However, IL6 trans-
signaling, which involves the shedding of IL6R by TACE, has only recently been 
identified in cancer. Indeed, high levels of IL6 and sIL6R correlate to decreased 
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survival/increased metastasis and adverse outcomes in breast cancer patients, respectively 
[149-151]. The mechanism for IL6 trans-signaling involves the shedding of IL6R from 
the surface of IL6R positive cells, the binding of soluble IL6R to soluble IL6 forming a 
complex that activates IL6 signaling in IL6R positive or negative cells through binding to 
the ubiquitously expressed GP130 receptor (Figure 2.2) [152]. IL6 trans-signaling leads 
to downstream activation of janus kinase / signal transducer and activator of transcription 
3 (JAK/STAT3) [152] and of nuclear factor kappa B (NFĸB) [153], two pathways linked 
to cancer progression [154-156]. Moreover, JAK/STAT3 signaling in macrophages leads 
to cell polarization and an M2 pro-tumor phenotype [74] with enhanced secretion of 
cancer stem cell promoting factor, IL1β and IL6 [157], angiogenic molecules, VEGF and 
bFGF [158], and the immunosuppressive enzyme, arginase 1 (arg1) [159]. Recent studies 
on trans-signaling demonstrate that sIL6R acts as a reservoir for IL6 by extending its half 
life as well as a mechanism for amplifying IL6 signaling on both IL6R expressing and 
non-expressing cells [152]. Therefore, TACE activation may be one of the mechanisms 
used by tumor cells to amplify IL6 signaling, the activation of which promotes the 
display of primarily pro-tumor functions by macrophages. 
In addition to the effects of tumor cell TACE-shed substrates on TAMs, these 
substrates also affect other cell types present in the tumor microenvironment involved in 
breast cancer progression. For example, TACE-shed substrates affect the activities of 
endothelial cells leading to alterations in endothelial cell morphology, proliferation and 
invasion in vitro and neo-vascularization in vivo [160,161]. Since the adhesion to 
endothelial cells within the tumor mass is a key step in macrophage recruitment to the 
tumor site, the critical role of the interactions between tumor cells and endothelial cells 
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mediated by TACE in the process of macrophage recruitment cannot be overlooked. 
Indeed, VCAM1, ICAM1, L-selectin and very late antigen 4 (VLA4), all targets of 
TACE, are key mediators of leukocyte adhesion to the vascular endothelium [162,145]. 
Thus, a better knowledge of the multiple TACE activities in the tumor microenvironment, 
especially its effects on the stromal components may further our understanding of TACE 
activities within the tumor microenvironment and translate into improved therapeutic use 
of current and future TACE inhibitors. 
2.9 New Therapeutic Avenues and Future Research Axes 
2.9.1 TACE Inhibition 
TACE expression and activities have shown promise as prognostic indicators in 
breast cancer. Indeed, elevated plasma TACE concentrations were an independent 
predictor of decreased breast cancer patients’ overall survival [163,91]. Additionally, 
increased TACE mRNA concentrations in the tumor mass were predictive of poor 
prognosis in breast cancer [7]. These observations and others [93] strongly imply the 
involvement of TACE activities in cancer progression [75,78,60,7] and support the 
clinical targeting of TACE using either small molecule chemical inhibitors [164,165], 
pro-domain analogs [166], or monoclonal antibodies [94]. The currently available and 
studied TACE inhibitors are presented (Table 3). Thus far, INCB7839 is the sole TACE 
inhibitor clinically tested on a cohort of breast cancer patients [167]. In that phase II 
clinical trial, patients receiving INCB7839 treatment exhibited moderate stabilization and 
decreased levels of EGF ligands [167]. Many other TACE inhibitors have been tested for 
the treatment of autoimmune diseases, and were shown to be safe at the dose tested but 
the treatment efficacy was limited [168,169]. In these clinical studies, the effects of 
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TACE inhibition on TAMs including altered macrophage phenotype, infiltration and 
activities, however, were not addressed. Thus, based on the substrate released by TACE, 
inhibitors of this enzyme may decrease both recruitment and activation of pro-tumor 
TAMs within the tumor microenvironment, potentially altering the observed clinical 
responses. For example, inhibiting TACE on tumor cells decreases the concentrations of 
CSF1-shed in the tumor microenvironment, thereby reducing the chemotaxis, infiltration 
and activation of pro-tumor TAMs [71,20,57]. 
2.9.2 TAM Inhibition 
Ongoing approaches include the direct targeting of TAMs (detailed in Table 3). 
Methods modulating the presence and activities of macrophages at the tumor site through 
direct targeting of the pro-tumor effects of TAMs are under investigation 
[170,87,171,172]. For instance, the well-tolerated macrophage inhibitor PLX-3397 
combined with other therapies was tested in the phase II clinical trial in patients with 
Hodgkin lymphoma [173]. In that trial, PLX-3397 led to significant decreases in both 
circulating monocytes and CTLs [173]. A similar treatment strategy with PLX-3397 in 
combination with chemotherapy for the treatment of triple negative metastatic breast 
cancer provided supportive preclinical data [12]. Currently patients with metastatic breast 
cancer are being recruited for a phase II clinical trial to determine the efficacy of PLX-
3397 for treatment of metastatic breast cancer [174]. Oral administration of the 
macrophage inhibitor Clodronate for the treatment of early stage breast cancer led to 
decreased recurrence and metastasis in women over the age of 50 [175]. By decreasing 
pro-tumor TAM abundance in breast tumors, TACE inhibitors may have similar effects 
to macrophage inhibitors. Thus far, the data available supports the use of TACE 
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inhibitors as an additional approach to prevent pro-tumor macrophages, thereby limiting 
breast cancer progression.  
2.10 Future Prospects and Challenges 
The pro-tumor effects of TACE activation have been demonstrated in multiple 
solid tumors including breast cancer. The data strongly suggest that either targeted TACE 
inhibitors or inhibitors of TACE substrates that focus on the tumor / stroma cell 
interactions may have therapeutic benefits. Indeed, in addition to the autocrine effects of 
tumor cell TACE activities on tumor progression, data collected in the past decade 
indicate a clear link between TACE activities / the distribution of immuno-modulatory 
TACE substrates and TAMs infiltration, phenotype and functions. TACE inhibition 
prevents autocrine tumor growth factor signaling and may hinder pro-tumor macrophages 
within the breast tumor microenvironment. Specifically, targeted TACE inhibition may 
decrease the abundance and activation of pro-tumor TAMs within the breast tumor 
microenvironment.  
Given the multiple effects of TACE inhibitors on both tumor and stroma cells, 
such a therapeutic approach, depending on the route, dose and schedule, will likely 
modulate both macrophage trafficking and activation. To improve TACE-derived 
therapeutic approaches, a better understanding of the effects of TACE inhibition on 
macrophages and other stromal cells is needed. Indeed, successful targeted therapies are 
always initiated by concrete and encompassing basic research. Furthermore, the transition 
from thinking of tumors as populations of transformed cells towards a complex organ 
involving multiple cell-cell interactions supporting malignancy makes understanding a 
therapies effect on the microenvironment of great interest. Options including targeting 
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TACE on specific cell types or specific areas of the tumor to minimize undesired side 
effects on the tumor microenvironment may prove more efficacious than systemic 
inhibition. Furthermore, defined subsets of breast cancer patients may benefit from 
TACE inhibitor treatments, based on the heterogeneity of their tumors, especially those 
patients with increased TAM abundance.  
Such approaches as targeting specific substrates of TACE, modulation of TACE 
activities and TAM infiltration within the tumor mass will provide new targeted 
therapeutic approaches to treat breast cancer patients but come with their own sets of 
challenges. First, mutations in TACE, although rare, may generate tumors which are 
unresponsive to TACE inhibition. In this case downstream substrates may provide better 
targeting options. Next, deciding which downstream TACE substrates are most 
appropriate to target will vary patient to patient depending on the makeup and 
composition of the breast tumor microenvironment. For example, CSF1 may be a suitable 
target in tumors with increased TAM abundance whereas targeting ICAM1 or L-selectin 
targeting would benefit patients with increased vasculature or lymphocyte abundance, 
respectively. Finally, developing chemical inhibitors that specifically inhibit the 
catalytically active conserved metalloproteinase domain of TACE thus far have proven 
difficult. Although, more specific chemical inhibitors are being developed the use of 
monoclonal antibodies or pro-domain analogs may be more suitable to target TACE.  
In conclusion, a full understanding of the effects TACE inhibition on both tumor 
cells and stoma cells will improve our ability to appropriately and proficiently treat breast 
cancer patients.   
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2.11 Tables and Figures 
 
 
TABLE 2.1. TACE substrates expressed during mammary development and / or breast 
tumorigenesis 
 
Classification & 
Substrates 
Mammary development References 
 Normal Cancer 
Growth factors 
AREG √ √ [97] [114] [7] 
HB-EGF √ X [176] [18] [177] 
TGFα √ √ [97] [111] [7] 
Cytokines 
TNFα √ √ [178] [179] [180] 
[181] 
Fractalkine X √ [182] [183] [184] 
Receptors 
TNFR1 √ √ [185] [123] 
TNFR2 √ X [186] 
M-CSFR √ √ [187] [188] 
NOTCH √ √ [189] [190] 
Adhesion molecules 
ICAM1 X √ [134] [132] 
VCAM1 X √ [70] [136] [131] 
L-selectin X √ [55] [191] 
Other 
APP √ √ [192] [15] 
MUC1 X √ [193] [194] 
√ - denotes the molecules involvement in either normal mammary development or 
mammary cancer progression.  
X - denotes unknown / untested effects on normal mammary development or mammary 
cancer progression. 
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TABLE 2.2. TACE substrates involved in macrophage activation, migration and 
apoptosis 
 
Substrates Macrophage functions References 
 Activation 
(alternative)  
Migration Apoptosis 
CSF1 + + - [20] [42] [57] 
CSFR1 + + - [20] [42] 
TNFα - + - [195] [196] 
TNFR1 + - + [197] [196] 
TNFR2 + - + [197]  
TGFα + NA + [198] [199] 
AREG + - - [200]  
IL1Rα + - - [201]  
MUC1 + + - [139] [13] [202] 
VCAM1 + + - [70] [137] 
ICAM1 - + - [203] [204] 
L-selectin - + - [205] [206] 
LAG3 - NA NA [207] 
CD30 - + NA [208] [209] 
CD40 - NA - [210] [211] 
IL6R - NA - [212] [23] 
Fractalkine (CX3CL1) NA + - [213] [214] 
CXCL16 + + NA [215] [216] 
JAM-A - + NA [217] 
MICA - NA NA [218] [218] 
+ and – denote whether the molecule positively or negatively affects the alternative (M2) 
activation, migration and/or apoptosis of macrophages, respectively. NA indicates that 
the molecule has no known effect on that specific macrophage function. 
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TABLE 2.3. TACE inhibitors and macrophage targeted treatments currently available 
(and / or under investigation) 
 
Classification & 
Name 
Targets(s) Manufacturer References 
TACE inhibitors 
WAY-022 TACE Wyeth-Aherst [164] 
TMI-2 TACE Pfizer [165] 
INCB3619 TACE, ADAM10 Incyte [219] 
INCB7839 TACE, ADAM10 Incyte [220] 
GW280264X TACE, ADAM10 Glaxo Smith Kline [221] 
TAM inhibition approaches 
Anti-CPG/IL-10 M2s [170] 
Bindarit CCL2, MCSF [87] 
PLX3397 Macrophages / mast 
cells 
Plexxikon [173] 
Type 1 IFNα TAMs [222] 
Trabectedin TAMs Johnson and 
Johnson 
[223] 
Clodronate 
liposomes 
TAMs [85] 
Liposome TAMs [224] 
HRG PDGF [171] 
Silibinin NFĸB, STAT3 [172] 
Legumain TAMs [225] 
LCL-PLP TAMs [226] 
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Figure 2.1. The different outcomes of TACE / ADAM17 shedding in autocrine / 
paracrine cell signaling. TACE is involved in proteolytic ectodomain shedding of 
membrane-
and sVCAM1 are free to bind to and activate EGFR, TNFRs and α4β receptors 
(VLA4/α4β1 and α4β7). This ligand / receptor interaction can be either autocrine or 
paracrine leading to downstream signaling in both effectors and target cells. 
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Figure 2.2. TACE activation and shedding of sIL6R in IL6 trans-signaling. Outline of IL6 
trans-signaling mediated by TACE. TACE shedding of IL6R produces sIL6R, the initial 
step in IL6 trans-signaling. Next, sIL6R binds to free IL6 in the microenvironment and 
this complex binds to the universally expressed signal transducer, gp130. The sIL6R/IL6 
complex has a longer half life than IL6 alone. This process stimulates downstream 
activation of IL6 signaling pathways including JAK/STAT3 and NFκB. 
  
 
CHAPTER 3: SOLUBLE TUMOR NECROSIS FACTOR RECEPTORS SHED BY 
BREAST TUMOR CELLS INHIBIT MACROPHAGE CHEMOTAXIS 
 
3.1 Abstract 
Breast tumor cells alter their microenvironment in part through the expression of 
pro-tumor molecules that influence macrophages during tumor progression and 
metastasis. Macrophage recruitment is stimulated by chemotactic factors including tumor 
necrosis factor alpha (TNFα) which also stimulates the cytotoxic/tumor cell killing 
macrophage phenotype. Through TNFα converting enzyme (TACE/ADAM17) activities, 
breast tumor cells shed membrane-bound proteins including their TNF receptors 
(sTNFR1/2), which serve as decoys sequestering TNFα and preventing TNFα-driven 
apoptosis of tumor cells, thereby decreasing TNFα bioavailability. Here, we investigated 
the levels of sTNFRs shed by breast tumor cells and determined the effects of shed 
sTNFRs on macrophage migration toward TNFα. TNFα and sTNFRs concentrations 
were measured in murine normal epithelial, stromal, and mammary tumor cells. The 
migration of murine macrophages towards TNFα in the presence of tumor derived 
soluble factors (TDSFs) shed by TACE was determined. TNFα concentrations secreted 
by tumor and normal epithelial cells were below the detection limit contrasting with 
stromal cells, especially macrophages, which expressed higher levels of TNFα (p<0.001). 
Regardless of the cell tested, treatment with the TACE inhibitor TAPI-0 led to a 
significant decrease in sTNFR2 shed (p<0.05). The dose-dependent macrophage 
migration toward TNFα prevented by incubation with TDSFs was not observed with 
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TDSFs collected following TAPI-0 treatment (p<0.05). Furthermore, the TNFα -driven 
increased pAkt expression in macrophage was inhibited by TACE shed TDSFs (p<0.05). 
These results highlight the role of tumor-shed sTNFRs in TNFα -driven macrophage 
chemotaxis. 
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3.2 Introduction 
Breast cancer is a common malignancy among women with significant mortality 
associated with the development of metastasis, and a 5-year survival rate of 23% for 
women with metastatic breast cancer at diagnosis [227,1,2].  The invasion and metastatic 
spread of breast cancer is greatly influenced by the tumor microenvironment [5]. 
Furthermore, the effectiveness and outcome of the standard of care for late stage breast 
cancer, which includes radiation and surgical resection and/or systemic chemotherapy 
and hormone therapy [228] heavily relies on the composition and expression profile of 
the microenvironment [229].  
The breast tumor microenvironment consists of non-malignant cells that infiltrate 
the developing tumor including fibroblasts, adipocytes, endothelial cells and immune 
cells, all of which may enhance cancer progression [230]. Tumor associated macrophages 
(TAMs) account for a large fraction of the infiltrating immune cells within most breast 
tumor masses and their presence has been linked to poor prognosis [14,231]. The 
phenotype of TAMs is similar to M2 macrophages, which are associated with wound-
healing properties [43]. In contrast to M1 macrophages which promote cytotoxicity, M2 
macrophages through their cytokine and chemokine expression promote tumor growth 
and invasiveness [43,38]. TAMs contribute to tumor progression and invasion through 
remodeling of the extracellular matrix (ECM), release of growth and angiogenic factors 
and suppression of antitumor immune responses [22,14]. 
At the tumor site, the macrophages are influenced by various physical and 
chemical interactions with the tumor and surrounding microenvironment. Some early 
inflammatory cytokines expressed in the tumor mass include tumor necrosis factor alpha 
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(TNFα) and colony stimulating factor 1 (CSF-1) [232,233]. TNFα is expressed by 
multiple cell types including tumor cells, macrophages, and adipocytes [234,59,235]. The 
binding of TNFα to either one of its receptors, TNF Receptor 1 (TNFR1) or TNFR2 
promotes tumor cell apoptosis or survival respectively, but also stimulates macrophage 
migration and secretion of pro-inflammatory molecules further promoting macrophage 
infiltration [8,236]. The TNFα binding to TNFR1 activates c-Jun N-terminal kinases 
(JNK) and c-Jun, whereas TNFα binding to TNFR2 led to the activation of Akt in various 
cells including macrophages [237,49]. In particular, TNFα promotes 
monocyte/macrophage invasion through positive chemotaxis and has been associated 
with increased metastasis [234,59]. The TNFα signaling pathway is modulated by various 
factors including lipopolysaccharide (LPS), transforming growth factor β (TGF-β) and 
interleukin 10 (IL-10) [238,24]. This pathway is also modulated by the bioavailability of 
both TNFα and TNFRs within the tumor microenvironment. Indeed, cells through 
ectodomain shedding by TNFα converting enzymes (TACE) release both TNFα and 
soluble (sTNFRs) which can neutralize the response to shed TNFα thereby preventing 
TNFα signaling [239]. Increased expression of TACE in breast tumor cells is linked to 
poor prognosis [7]. Although the general mechanisms of the shedding of sTNFRs and 
TNFα is well understood [109,78], the role of the TACE activity of breast tumor cells on 
the migration of macrophages has yet to be fully investigated.  
Increased local and systemic concentrations of shed molecules including TNFRs, 
CSF-1 and CSF-1R have been implicated in inflammatory/autoimmune diseases and 
some malignancies [240,64]. A link between serum concentrations of sTNFR in breast 
cancer patients and poor prognosis has not been demonstrated [241], possibly because the 
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serum sTNFR concentrations significantly differ from the sTNFR concentrations within 
the tumor [242]. Indeed, in addition to sTNFRs expression that has primarily been 
assessed in immune cells [243,244], both adipocytes and breast tumor cells also shed 
sTNFRs and CSF-1 [64,20].  
Whether sTNFRs shed by tumor cells through TACE activities modulate the 
chemotaxis of macrophages toward TNFα is unknown. Here we investigated the 
chemotaxis and signaling of macrophages toward TNFα in the presence of tumor derived 
soluble factors (TDSFs) collected following treatments with or without a sheddase 
inhibitor. Results underline the role of sTNFRs in modulating macrophage chemotaxis. 
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3.3 Materials and Methods 
Cell culture conditions 
Murine mammary epithelial cells NMuMG, carcinoma cells 4T1, endothelial cells 
2H11, and mesenchymal stem cells D1 were obtained from ATCC (Manassas, VA). 
Murine mammary cells 67NR and 4T07 were a generous gift from Dr. Miller (Karmanos 
Cancer Institute, Detroit, MI). Media supplies were obtained from Mediatech (Herndon, 
VA). Epithelial and endothelial cells were cultured at 37°C and 5% CO2 in DMEM media 
supplemented with 10% FBS, gentamycin, and amphotericin B. For NMuMG and D1 
cells, media was also supplemented with 10µg/ml of insulin and 4 mM glutamine 
(SigmaAldrich, St. Louis MO), respectively. Adipocytes were derived from D1 cells 
following incubation with a differentiation treatment composed of 100 µg/ml insulin, 0.5 
µM dexamethasone (SigmaAldrich), and 0.5 mM isobutylmethylxanthine (SigmaAldrich) 
for 48 hours [58]. To block the shedding of TNFRs, 4T1 and NMuMG cells were treated 
with the TACE inhibitor TAPI-0 diluted in DMSO (250 nM; CalBiochem, Rockland, 
MA) for 24 hours. 
The macrophage J774.2 and RAW264.7 (here on referred to as J774 and RAW, 
respectively) cells were obtained from ATCC. These cells were cultured in DMEM 
supplemented with 10% FBS, 1.5g/l NaCO3, 4.5g/l glucose, 4 mM glutamine 
amphotericin B and gentamycin (all reagents were obtained from Mediatech). 
Collection of conditioned media 
Conditioned media (CM) was obtained as described previously [58,245]. The 
collection time was optimized through a time curve and 48 hour incubations were 
optimal. Briefly, epithelial (NMuMG, 4T1), endothelial (2H11), pre-adipocyte (D1), 
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differentiated adipocyte and monocyte (J774, RAW2674.7) cells were cultured in media 
described above at 37°C and 5% CO2. For tumor cells, conditioned media (CM) contains 
tumor-derived soluble factors (TSDFs), and thus TDSFs is used to refer to 4T1 CM. Once 
cells reached 90% confluence serum free media with TACE inhibitor treatment (TAPI-0) 
or vehicle control (DMSO) was added for 24 hours. Treatments were removed by 
washing twice with phosphate buffer saline (PBS) and cells were incubated in 7 ml RPMI 
media depleted of serum and phenol red. Following a 48 hour incubation, the CM was 
collected, filtered (0.2 µm) and stored at -20°C. The volume of each conditioned medium 
was adjusted to 1 ml/10
6
 cells based on the number of cells present in the culture vessel 
as determined by Trypan blue cell counting at collection time. 
Immunocytochemistry Analyses 
J774 and RAW cells (50,000 cells/well) were seeded in 8 well chamber slides and 
allowed to grow for 24 hours until confluent. Cells were fixed with 4% paraformaldehyde 
(PFA) for 15 minutes at 37ºC and blocked with 1% bovine serum albumin (BSA) for 30 
minutes and then incubated with either anti-TNFR1 or anti-TNFR2 antibodies for 1 hour 
at room temperature. After washing, cells were incubated with a fluorophore (Texas red) 
- conjugated secondary anti-rabbit antibody for 1 hour at room temperature. Cells were 
stained with the vital dye Hoechst and mounted with VectaShield (Burlingame, CA). The 
presence of either TNFR1 or TNFR2 was visualized using a IX71 fluorescent microscope 
(Olympus) and microphotographs were taken using similar conditions of fluorescence 
illumination for a given set of immune-stained samples and similar conditions of 
magnification (Size is denoted by a bar on microphotographs) using a DP70 camera 
(Olympus). 
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Transwell Chemotaxis Assays 
J774 and RAW macrophage cells (60,000 cells/well) were seeded in serum-free 
media supplemented with the vital nuclear dye Hoechst (1:2000 dilution) in the top 
chamber of transwell migration chambers in 24 well plates. The lower chambers were 
filled with 500 µL (1:2 dilution) of either TDSFs collected after treatment with or without 
TAPI-0 (250 nM) in the presence or in the absence of TNFα (0.5ng-15ng) or control 
media (0% FBS, 10% FBS for negative and positive controls, respectively). After 6 
hours, cells were removed from the upper side of the transwell membrane using a cotton 
swab and microphotographs of the cells attached to lower side of the membranes were 
taken (at least 5 random fields; 200x magnification), counted and the number of 
macrophages that migrated was normalized to the total transwell membrane surface area. 
TNFα and sTNFRs ELISAs 
TNFα and sTNFR levels were assessed using ELISAs conducted following the 
manufacturer’s recommendations (R&D Systems, Minneapolis, IN) with all steps 
conducted at room temperature. Briefly, 96-well plates were coated with the capture 
antibody and incubated overnight. Following blocking with 1% bovine serum albumin for 
1 hour, CM samples were added, and the plates were incubated for 2 hours. In the 
subsequent incubations, a biotin conjugated detection antibody and streptavadin-
Horseradish Peroxidase (HRP) were added for 60 and 20 minutes, respectively. The 
presence of HRP-conjugated complexes was determined following the addition of the 
substrate solution (TMB, Pierce Inc. Rockford, IL) and the enzymatic reaction stopped by 
the addition of H2SO4 (2N). Optical densities (450 nm) resulting from HRP activities 
were measured using a microplate reader (Biotek, Winooski, VT) and based on standard 
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curves ran along with the samples, TNFα and sTNFRs were expressed in pg/ml per 10
6
 
cells. 
Western Blots 
Protein lysate immunoblotting was conducted as described earlier [246]. Briefly, 
25 µg of total protein per well were loaded on 8% polyacrylamide gels and run in SDS-
PAGE denaturing conditions and the proteins were then transferred onto nitrocellulose 
membranes. Loading of equal protein amounts was assessed by staining membrane with 
0.1% Ponceau S (Sigma) in 5% acetic acid and further assessed by evaluating the 
presence of ß-actin by immunoblots. After a 1-hr incubation with TBS-T (0.1% Tween 
20) containing 5% nonfat milk to block non-specific binding, membranes were incubated 
with antibodies specific for Akt and pAkt (Santa Cruz biotechnology), pJNK and cJun 
(Cell signaling, Danvers, MA) or β-actin (SigmaAldrich, St Louis, MO). Following a 
one-hour incubation with the appropriate HRP-conjugated secondary antibody and the 
addition of a chemiluminescent substrate (Pierce, Rockford, IL), the presence of protein 
was detected using a biochemiluminescent imaging system and the VisionWork software 
(UVP, Upland, CA).  Differences in protein expression were evaluated by densitometry 
using Quantity One software (Biorad, Hercules, CA) following normalization to ß-actin 
expression. 
Flow Cytometry 
Following cell collection using trypsin (epithelial cells) or scraping 
(macrophages), cells were fixed with 1% PFA for 30 minutes at room temperature and 
resuspended in PBS supplemented with 1% BSA. The presence of TNFR1 and TNFR2 
surface receptors was determined by cell surface staining using antibodies specific for 
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TNFR1 and TNFR2, respectively. Briefly, resuspended cells were incubated with either 
anti-TNFR1 or anti-TNFR2 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) for 
45 minutes at 4ºC. Cells were then washed twice with PBS and incubated with 
appropriate FITC-conjugated secondary antibody (Invitrogen, Grand Island, NY). 
Control stain included the secondary antibody alone. Following additional washes, the 
presence of cell surface TNFR1 and of TNFR2 cells was monitored by flow-cytometry 
(Fortessa cytometer, Becton Dickinson, San Jose, CA, USA). Analyses were conducted 
using the CellQuest software and graphical representation was obtained using FlowJo 
software. Data are presented as percentage of positive cells for either TNFR1 or TNFR2. 
The control corresponding the background stain associated with the secondary antibody 
is displayed on each histogram.   
Statistical Analyses 
All data were expressed as mean ± SEM. Statistical analyses were conducted 
using one-way ANOVAs and Newmann-Keul post-hoc tests (Prism, Graphpad Software, 
Inc., La Jolla, CA). Significance was set a priori to p value below 0.05. A correlation 
between concentration of TAPI-0 and sTNFR2 excretions was determined using a linear 
regression analysis of log transformed values. 
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3.4 Results 
TNFα is secreted by mammary stromal cells, in particular macrophages but not epithelial 
or tumor cells 
First, we determined whether TNFα, which is mainly produced by stromal cells, 
and often found at high levels in breast carcinomas, was secreted by the murine cells 
investigated here by ELISA in conditioned media (CM) from each cell type. TNFα was 
not detected (ND or below the detection limit) in the CMs collected from the non-
invasive (67NR), non-metastatic (4T07) and metastatic (4T1) murine mammary 
carcinoma cells or murine epithelial cells (NMuMG) (Fig. 3.1A). In contrast, TNFα was 
present in the culture media of murine mesenchymal D1 stem cells, differentiated 
adipocytes and 2H11 endothelial cells (Fig. 3.1A). The J774 and RAW macrophage cells 
secreted between 10-fold and 40-fold higher concentrations of TNFα than other stromal 
cells (p<-.005, Fig. 3.1B). Furthermore, the expression of TNFα varied among the 
macrophage cells tested with much higher levels of TNFα in the CMs collected from 
RAW cells (p<0.001). 
TNFR1 and TNFR2 are expressed on the cell surface of macrophages and tumor cells 
As TNFα signaling is initiated through binding of TNFα to one of its two cognate 
receptors TNFR1 or TNFR2 bound to the cell membrane, using immunocytochemistry 
(ICC), Western blots and flow cytometry, we investigated TNFR1 and TNFR2 
expressions on murine macrophages. TNFRs were expressed by both J774 and RAW 
macrophages as assessed by ICC (data not shown), Western blots (data not shown) and 
flow cytometry (Fig 2A, B). The tumor cells tested by flow cytometry expressed TNFRs 
regardless of their metastatic potential (Fig. 3.2A, B). Interestingly, whereas the 
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expression of TNFR1was comparable between the cells tested, the expression of TNFR2 
was consistently higher in the metastatic 4T1 cells as compared to the non-invasive 67NR 
and non-metastatic 4T07 cells (Fig. 3.2B). 
sTNFR1 and sTNFR2 are shed by mammary epithelial and cancer cells and this shedding 
can be blocked through  incubation with the TACE inhibitor TAPI-0 
To determine whether TNFR1 and TNFR2 are shed through ectodomain 
shedding, the soluble forms of TNFR1 (sTNFR1) and TNFR2 (sTNFR2) were measured 
by ELISA in secretions from 4T1 and NMuMG cells. Both sTNFR1 and sTNFR2 were 
present in CMs from 4T1 and NMuMG cells with sTNFR1 concentrations similar 
between 4T1 and NMuMG cells (Fig. 3.3A). Concentrations of sTNFR2 in 4T1 CM was 
significantly higher than concentrations of sTNFR1 in 4T1 CM and sTNFR2 in NMuMG 
(5.6 fold and 1.8-fold, respectively, p<0.001, Fig. 3.3A).  
The chemical inhibition of TACE through incubation with the TACE/ADAM-17 specific 
inhibitor TAPI-0 led to a dose-dependent decrease in sTNFR2 concentrations in 4T1 CM 
(r
2
=0.9634, p=0.0185, Fig. 3.3B). Compared to vehicle treatment, the incubation with the 
TACE/ADAM-17 specific inhibitor TAPI-0 at 250 nM led to significant decreases in 
sTNFR2 concentrations in both NMuMG and 4T1 CMs (p<0.05, Fig. 3.3B). 
TNFα-driven macrophage chemotaxis is inhibited by 4T1 TDSFs but not by 4T1 TDSFs 
collected following treatment with the TACE inhibitor TAPI-0 
Next, we investigated whether sTNFRs present in 4T1 tumor CMs modulated 
TNFα-driven macrophage chemotaxis, by sequestering TNFα. Increasing concentrations 
of TNFα led to a dose-dependent increase in the chemotaxis of J774 macrophages (Fig. 
3.4A, B) and RAW macrophages (Fig. 3.4C, D). The addition of 4T1 CMs inhibited the 
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chemotaxis of both J774 and RAW macrophages towards either 1.5 or 15 ng/ml 
concentrations of TNFα (Fig. 3.4A-D). 
In contrast, the 4T1 CMs collected following treatment with the TACE/ADAM17 
inhibitor, TAPI-0 and thus containing lower sTNFR concentrations did not inhibit the 
TNFα-driven macrophage chemotaxis (p <0.001, Fig. 3.5).  
The TNFα-driven macrophage chemotaxis is in part mediated through the Akt pathway 
and blocked by tumor TACE-shed molecules 
To ascertain whether specific pathways downstream of TNFα/TNFR signaling 
were involved in the observed alterations of macrophage chemotaxis led by 4T1 TDSFs, 
the Akt and JNK pathways were analyzed in both J774 and RAW macrophages following 
activation and inactivation by TDSFs of the TNFα/TNFR signaling pathway. No 
significant differences were observed in total Akt, cJun, pJNK and β actin regardless of 
treatment (n.s., Fig. 3.6 A, D). However, the ratio of pAkt/total Akt protein expression in 
J774 and RAW macrophages was significantly increased following incubation with 
increasing TNFα concentrations (p<0.05, Fig. 3.6 B, C). This increase in pAkt/total Akt 
was inhibited by concomitant 4T1 TDSFs and TNFα treatments but not by concomitant 
treatments with TNFα and 4T1 TDSFs collected following TAPI-0 treatment (p<0.05, 
Fig. 3.6 A-C). 
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3.5 Discussion 
The pleitropic cytokine TNFα is expressed in breast cancer tissue and stimulates 
macrophage migration and activates cytotoxic macrophages (i.e., M1 macrophages); 
however, M1 macrophages are mostly absent within the breast tumor [59,38,247,195]. 
TNFα has been shown to promote chemotaxis of macrophages in various pathologies; 
however, its role in macrophage trafficking to the breast tumor site is unclear 
[247,248,8]. The primary mechanisms by which tumor cells alter macrophages include 
release of immunomodulatory factors (CSF1, CCL2, CCL5) leading to increased 
recruitment and stimulation of alternatively activated macrophages (i.e., M2) [8,119,25]. 
Importantly, the shedding activities of TACE/ADAM17, highly expressed by cancer cells 
[7], leads to the release of TNFRs. However, the role of TACE activities and tumor shed 
TDSFs on TNFα-driven macrophage chemotaxis remains to be addressed. Furthermore, 
whether the observed TNFα-driven recruitment of macrophage to inflamed tissues is 
through either activation of TNFR1 or TNFR2 which stimulate the JNK and Akt 
signaling pathways, respectively, in breast cancer is unclear [248,247,237,8]. Our data 
show that stromal cells including macrophages shown to be present in the breast tumor 
microenvironment secrete TNFα [8]. Furthermore, the results indicate that TNFα-driven 
macrophage chemotaxis is dose-dependent. More interestingly, our data highlight a 
mechanism by which mammary tumor cells alter the response of macrophages to TNFα 
by shedding their TNFRs through TACE activities leading to an inhibition of TNFα-
driven macrophage chemotaxis. In addition, our results suggest a role for the Akt 
pathway in the TNFα-driven macrophage chemotaxis. 
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The in vitro models used here to investigate the TNFα-TNFR signaling between 
tumor cells and macrophages have been utilized extensively to further our understanding 
of the pro-tumor microenvironment [19,249]. Despite their limitations, in vitro 2D and 
3D models of mammary tissues and breast cancer progression have proven invaluable in 
the assessment of the mammary microenvironment including the cell-cell interactions 
between tumor and stroma cells [19,249]. 
The results presented here confirm that the TNFα pathway is active in the tumor 
microenvironment through TNFα mainly secreted by stromal cells including 
macrophages and by signaling via the membrane-bound TNFR1 and TNFR2 expressed 
on the macrophage cells [250,251]. TNFα activates TNFR1 or TNFR2, the latter of 
which lacks a death domain, leading to either cell death or cell survival, respectively 
[252-254]. In line with a previous study [251], we show TNFR1 and TNFR2 are 
expressed by both malignant and stromal cells in the breast tumor including 
macrophages. Interestingly, here we further demonstrate TNFR2 levels are relatively 
higher in the metastatic tumor cells (4T1) as compared to non-metastatic tumor cells 
(4T07 and 67NR) and macrophages (J774 and RAW) (Figure 3.2B).  
The increased expression of TNFR2 may be one of the mechanisms by which 
breast tumor cells subvert apoptosis and promote their survival, as observed in colon 
cancer [255]. Alternatively, the pro-apoptotic effects of TNFα/TNFR signaling are 
diminished through the sequestration of TNFα by soluble forms of TNFR1 and TNFR2 
[256]. Our data highlight the shedding of TNFR especially TNFR2 through 
TACE/ADAM17 activities. The increase in sTNFR2 shed by tumor cells observed here 
may be associated with a higher cell surface expression and/or a preferential shedding of 
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TNFR2 by TACE/ADAM17. In addition, increased internalization of the receptors by 
normal cells may also be involved [257]. 
TNFα is present in the breast tumor microenvironment, however, its stimulation 
of tumor cell apoptosis has been shown to be prevented by tumor cells shedding TNFRs 
[256]. Macrophages also respond to TNFα concentrations present in the breast tumor 
microenvironment through both paracrine and autocrine signaling leading to prolonged 
inflammation caused by a positive feedback loop with TNFα [258]. The effects of TNFα 
on macrophage migration have been seldom studied in breast tumors. Our data indicate 
that tumor cells through the shedding of TNFR2 significantly inhibit the macrophage 
chemotaxis toward TNFα in part through inhibition of the Akt pathway. The inhibition of 
the TNFα stimulated Akt pathway downstream of TNFR2, but not of the JNK/c-Jun 
pathway, in macrophages by TACE-shed TDSFs strongly support the modulation of the 
infiltration and cytotoxic activities of the macrophage subsets within the tumor 
microenvironment. The inhibition of the TNFα-driven macrophage chemotaxis by tumor 
conditioned media and especially by TACE tumor-shed molecules highlight the 
importance of this mechanism. Furthermore, although the data presented do not address 
directly the macrophage infiltration of the tumor mass, the strong modulation of the 
macrophage chemotaxis and invasion observed here may interfere with the recruitment 
and or differentiation of cytotoxic macrophages within the tumor mass [247,8].  
Our observations, that sTNFRs shed by tumor cell TACE activity negatively 
impact the ability of TNFα to stimulate macrophage chemotaxis further underscore the 
pro-tumor role of TACE/ADAM17 [7,163]. Our results (not shown) and others 
demonstrate the presence and activities of TACE in all the epithelial and tumor cell tested 
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[7]. Tumor cell TACE activities shed many growth factors and immunomodulatory 
cytokines that play key roles in tumor progression [60]. Indeed, TACE inhibitors are 
currently in phase II clinical trials for a subset of metastatic breast cancer patients 
[167,259]. To date, clinical trials using TACE inhibitors have been unsuccessful partly 
because of the lack of specificity exhibited by inhibitors tested [75,60]. The data 
presented here suggest that the testing of more specific inhibitors may be more 
successful. Furthermore the targeting of sTNFRs especially sTNFR2 may also modulate 
both the infiltration of cytotoxic macrophages and/or the activation of cytotoxic 
macrophages within the breast tumor microenvironment that in turn may promote tumor 
regression. 
Taken together, our findings along with previous studies support a mechanism by 
which mammary tumor cells abrogate the TNFα signaling response in macrophages by 
shedding their TNFRs through TACE enzyme activities. This pathway offers many 
potential targets to promote the cytotoxicity of macrophages in the breast tumor beyond 
the direct actions on TNFα or TACE activities including interferences with the breast 
tumor concentrations of sTNFR1 and sTNFR2, respectively. Further validation of these 
observations may provide new avenues with more targeted approaches promoting the 
stimulation of the patient’s own immune system especially macrophages leading to the 
therapeutic benefit of the destruction of breast tumor cells. 
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3.6 Figures 
 
 
 
 
Figure 3.1. Mammary stromal cells but not epithelial or tumor cells secrete TNFα. CMs 
were harvested following a 24-hour serum starvation period and a 48-hour incubation 
with phenol red free RPMI of the following murine cells: (A) D1 mesenchymal stem 
cells, D1-derived adipocytes, 2H11 endothelial cells, NMuMG mammary gland epithelial 
cells, 67NR, 4T07 and 4T1 mammary tumor cells and (B) J774 and RAW macrophage 
cells. The volume of each CM solution was adjusted to 1 ml per 10
6
 cells counted at 
collection time. TNFα concentrations (pg/ml, mean ± SEM) were determined by ELISA. 
***p<0.001.  
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Figure 3.2. Both TNFR1 and TNFR2 are expressed by mammary tumor cells and 
macrophages. (A) TNFR1 and (B) TNFR2 surface receptor expression (white area) 
represented as percent positively stained cells assessed by flow cytometry. The 
background is measured by only staining cells with fluorescently labeled secondary 
antibody (grey area).  
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Figure 3.3. 4T1 mammary tumor cells shed more sTNFR2 than sTNFR1 and treatment 
with the TACE inhibitor TAPI-0 prevented sTNFR2 shedding. (A) Both CM from 
NMuMG (open bars) and 4T1 (darkened bars) cells contained sTNFR1 and sTNFR2 
(pg/ml per10
6
 cells ± SEM) as determined by ELISA. sTNFR1 concentrations present in 
CMs from both cells were not significantly different. The sTNFR2 concentration in 4T1 
CM was significantly higher than the concentration of sTNFR1 (5.6-fold for 4T1, 
p<0.05). Furthermore, the concentration of sTNFR2 was much higher in 4T1 TDSFs than 
sTNFR2 in NMuMG CM (p<0.001). (B) Incubation with increasing doses of the TACE 
inhibitor TAPI-0 was associated with a significant decrease in sTNFR2 present within 
4T1 (open bar) and NMuMG (darkened bar) CMs. The decrease in sTNFR2 was dose-
dependent from 0 to 250 nM of TAPI-0 (physiologic dose – 50 mg/kg (Han and others 
2010)). The treatment with 250nM of TAPI-0 led to a significant decrease in sTNFR2 
present in 4T1 TSDFs and NMuMG CM. **p<0.01, ***p<0.001.  
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Figure 3.4. TNFα-driven macrophage chemotaxis is inhibited by factors in 4T1 TDSFs. 
J774 (A, B) and RAW (C, D) macrophage chemotaxis towards increasing concentrations 
of TNFα with or without TDSFs was assessed using transwell assays (see materials and 
methods for details). (A, C) Representative microphotographs (bar = 100 µm) of the 
chemotaxis of J774 (A) and RAW (C) cells. All microphotographs were taken at the 
same magnification and inverted. Briefly, macrophages stained with the vital dye 
Hoechst were resuspended in serum free media and placed in the top wells of transwell 
inserts and allowed to migrate toward (a) serum free media, (b) 1.5 and (c) 15 ng/mL 
TNFα or (d) 4T1 TDSFs (1:2 dilution) alone or 4T1 TDSFs (1:2 dilution) and (e) 1.5 or 
(f) and 15 ng/ml of TNFα for 6 hours. (B, D) Quantifications of J774 (B) and RAW (D) 
macrophage chemotaxis. Following chemotaxis, cells were counted and expressed as 
total number of migrated cells per well (average ± SEM). The data presented are 
representative of at least three independent experiments. ***p<0.001 and **p<0.01. 
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Figure 3.5. TACE-shed TDSFs decrease TNFα-driven macrophage chemotaxis. (A, B) 
representative microphotographs (bar = 100 µm) of J774 (A) and RAW (B) macrophage 
chemotaxis. Briefly, the TNFα-driven chemotaxis of J774 and RAW cells with or without 
TDSFs or with TDSFs collected following TAPI-0 treatment was assessed using 
transwell assays. All the microphotographs were taken at the same magnification and 
inverted. Macrophages stained with the vital dye Hoechst were resuspended in serum free 
media and placed in the top wells of transwell inserts and allowed to migrate toward (a) 
serum free media, (b) 4T1 TSDF (1:2 dilution) (c) 15 ng/mL TNFα or (d) 4T1 TDSFs 
collected following TAPI-0 treatment (TAPI-0 4T1 TSDFs) or (e) the combination TAPI-
0 4T1 TSDFs and TNFα for 6 hours. (C, D) Quantifications of the chemotaxis of J774 
(C) and RAW (D) macrophages. Following chemotaxis, cells were counted and 
expressed as total number of migrated cells per well (average ± SEM). The data 
presented are representative of at least three independent experiments. *** p<0.001 and 
** p<0.01.  
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Figure 3.6. The expression of pAkt is increased in TNFα-stimulated J774 and RAW 
macrophages incubated with 4T1 TDSFs collected following TAPI-0 treatment. (A) 
Representative immunoblots of pAkt, Akt and β actin expressions by J774 (A-left panel) 
and RAW (A-right panel) macrophages following treatment with TNFα, 4T1 TDSFs 
and/or TDSFs collected following TAPI-0 treatment. The ß-actin expression served as 
loading control (see material and methods for details). (B, C) Quantification of the 
expression of key downstream molecules involved in TNFR signaling. The ratio of 
pAkt/total Akt protein expression in J774 (B) and RAW (C) macrophages were 
significantly increased following incubation with TNFα. This increase was inhibited by 
concomitant 4T1 TDSFs treatment but not by but not by 4T1 TDSFs collected following 
TAPI-0 treatment. Data are presented as pAkt/total Akt intensity ratio (average ± SEM, 
no unit). 
  
 
 
CHAPTER 4: BREAST TUMOR CELL TACE-SHED MCSF PROMOTES PRO-
ANGIOGENIC MACROPHAGES THROUGH NF-κB SIGNALING 
 
 
4.1 Abstract 
Most deaths associated with breast cancer, the most common malignancy in 
women, are caused by metastasis. Tumor associated macrophages (TAMs) significantly 
contribute to breast cancer progression and development of metastasis through the 
promotion of angiogenesis which involves a central regulator of macrophage functions: 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ĸB). Macrophages are 
activated by macrophage colony stimulating factor (MCSF) and chemokine (C-C motif) 
ligand 2 (CCL2) to secrete angiogenic factors including vascular endothelial growth 
factor (VEGF). The release of macrophage colony stimulating factor from tumor cells is 
mediated by ectodomain shedding through tumor necrosis factor alpha converting 
enzyme activation (TACE). Here we determined whether tumor cells TACE-shed MCSF 
promotes angiogenesis through the activation of the NF-ĸB pathway in macrophages and 
the subsequent release of VEGF. These interactions were modeled in vitro using a panel 
of mammary cells mimicking the breast cancer progression from normal murine 
mammary gland (NMuMG) cells to metastatic 4T1 cells along with J774 macrophages, 
all derived from BALB/c mice. TACE and MCSF expressions were higher in metastatic 
cells  compared to epithelial cells (p<0.05). Tumor conditioned medias (CMs) activated 
the expression of VEGF by macrophages through the stimulation of NF-ĸB pathway and 
the resulting macrophage secretions that promoted high levels of endothelial cell tubes. 
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Furthermore, the combinations of CCL2, also highly expressed by tumor cells, and 
MCSF promoted pro-angiogenic macrophages. These results highlight the key role of 
tumor cell TACE-shed MCSF and secreted CCL2 in stimulating pro-angiogenic 
macrophages.  
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4.2 Introduction 
Breast cancer is the most commonly diagnosed malignancy among women with 
significant mortalities associated with the development of metastasis [1,2]. The 
progression and metastatic spread of breast cancer is greatly influenced by the tumor 
microenvironment [5]. Tumor associated macrophages (TAMs), in particular, are vital for 
both breast cancer progression and the successful dissemination of metastasis [14]. 
Indeed, TAM abundance correlates with both decreased survival and increased metastasis 
in breast cancer patients [14,231]. 
Macrophages can be activated to recognize and destroy malignant cells; however, 
the tumor promoting macrophage phenotypes are prevalent in the breast tumor 
microenvironment. Pro-tumor TAMs are characterized by secretion of factors that 
promote growth, chemotaxis, angiogenesis and remodeling of the extracellular matrix 
(ECM) [38,42]. The phenotype expressed by TAMs is stimulated by cues present in the 
breast tumor microenvironment including soluble immuno-modulatory factors produced 
by tumor cells [260]. Many of these soluble factors are released through tumor cell 
ectodomain shedding mediated by tumor necrosis factor alpha converting enzyme 
(TACE) [75], whose expression in breast tumors correlates with decreased patient 
survival [7]. TACE-shed molecules involved in tumor cell - macrophage interactions 
include macrophage colony stimulating factor (MCSF) [261], tumor necrosis factor 
(TNF) [76], epidermal growth factor receptor (EGFR) ligands [262] and intercellular 
adhesion molecule 1 (ICAM1) [75,263]. Of these TACE-shed molecules, MCSF 
regulates many pro-tumor functions of TAMs especially the promotion of tumor cell 
invasion and angiogenesis [14,42]. Furthermore, tumor cell - macrophage interactions 
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directed by MCSF also leads to cell streaming and the subsequent generation of the tumor 
microenvironment of metastasis [40]. The role of TACE activities in promoting pro-
tumor macrophages at the breast tumor site remains unclear. 
Macrophages infiltrate the breast tissue through chemotaxis stimulated mainly by 
cytokines including MCSF and chemokine (C-C motif) ligand 2 (CCL2) [21,264]. 
Furthermore, within the breast tissue, macrophages are activated by multiple factors of 
both stroma and / or tumor cell origin including MCSF and CCL2 [9,42]. Expressions of 
MCSF and its corresponding receptor MCSF receptor (MCSFR) have been linked to poor 
prognosis in breast cancer patients, mainly due to their roles in macrophage recruitment 
and activation [72,265]. Indeed, MCSF shed by tumor cells stimulates EGF production in 
macrophages leading to a paracrine feedback loop essential to tumor cell invasion and 
extravasation [122]. The roles of MCSF in the earlier steps of metastasis, including 
angiogenesis, have been demonstrated in many cancers [266]. In breast cancer, however, 
the role(s) and the mechanisms of MCSF in the early steps of cancer progression remain 
to be fully defined. 
MCSF stimulates macrophage production and secretion of the potent angiogenic 
factor vascular endothelial growth factor (VEGF). TAM release of VEGF is a major 
contributor to angiogenesis in tumors which is a rate-limiting step essential to tumor 
progression and metastasis [41,267,268]. As angiogenesis supports progression from pre-
malignant to malignant tumors, blocking vessel growth alone or in combination with 
other treatments has demonstrated significant benefits in patients with colon lung, kidney 
and brain cancers [269,270]. For example, the use of bevacizumab®, an inhibitor of 
VEGF-A, has been clinically successful [270]. However, this anti-angiogenic therapy had 
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no significant overall survival benefit for the treatment of patients with breast cancer 
[270,271]. The disparities between the benefits of anti-VEGF therapies in some cancers 
compared to breast cancer highlights the need for further understanding of breast tumor 
angiogenesis. 
In macrophages, VEGF expression and secretion are stimulated through multiple 
intracellular pathways especially the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-ĸB) signaling [48]. Indeed, both MCSF and CCL2 activate NF-ĸB 
signaling pathways in macrophages leading to increased survival and the release of 
factors that promote tumor cell invasion [272]. Typically upon activation of NF-ĸB 
signaling, IκB the inhibitor of κB is phosphorylated leading to its ubiquitination and 
proteasomal degradation allowing  active NF-ĸB dimers to translocate to the nucleus and 
initiate transcription [273,274]. These signaling events are critical for development / 
progression of cancer and macrophage VEGF release, but the characterization of the 
tumor cell macrophage interactions involved in promoting these events remains to be 
clearly understood in breast cancer [48,275]. 
Thus, we investigated whether breast tumor cell TACE-shed MCSF activated NF-
ĸB in macrophages leading to the production of VEGF and subsequent angiogenesis. The 
results indicate that tumor cell TACE-shed MCSF along with CCL2 stimulates pro-
angiogenic macrophages through the NF-κB signaling pathway.  
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4.3 Materials and Methods 
Cell lines and culture conditions 
Murine mammary carcinoma cells 4T1, mammary epithelial cells NMuMG, 
endothelial cells 2H11 and macrophages J774.2 (hereto forth referred to as J774) were 
purchased from ATCC (Manassas, VA, USA). 4T07 and 67NR cells were a generous gift 
of Dr. Miller (Karmanos Cancer Center Detroit MI). All cells (except J774 and NMuMG) 
were cultured at 37ºC and 5% CO2 in Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), gentamycin, and amphotericin B 
obtained from Mediatech (Herndon, VA, USA). NMuMG cells were cultured in the same 
media supplemented with 10 µg/mL insulin. J774 cells were cultured in DMEM 
supplemented with 10% FBS, 1.5g/l NaCO3, 4.5g/l glucose, 4 mM glutamine 
amphotericin B and gentamycin (all media reagents obtained from Mediatech). 
Collection of conditioned media 
Conditioned media (CM) were obtained as described previously [58,245]. Briefly, 
4T1 carcinoma cells were cultured in media described above at 37°C and 5% CO2 until 
90% confluent. Media was then replaced with serum-free media supplemented with either 
250 nM of the TACE inhibitor (TAPI-0) or the vehicle control (dimethyl sulfoxide 
(DMSO)) and cells were cultured for an additional 24 hours. Following washes with 
phosphate buffered saline (PBS) to remove treatments and an additional 48 - hour 
incubation in serum-free and phenol red-free RPMI media (7 ml), CMs were collected, 
filtered (0.2 µm) and stored at -20°C. Volumes of each CM were adjusted to 1 ml per 10
6
 
cells based on the number of cells present in the culture vessel as determined by Trypan 
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blue exclusion cell counting at collection time. Macrophage CMs were collected similarly 
following treatments with MCSF, CCL2 and/or specified 4T1 CMs. 
Inhibition of tumor cell TACE activities 
Carcinoma cells’ TACE shedding activities were inhibited through either 
incubation with the TACE specific inhibitor TAPI-0 (CalBiochem, Rockland, MA, USA) 
or specific TACE small interfering RNA (siRNA) (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA). Cells were incubated with the TACE inhibitor TAPI-0 (250 nM in 
DMSO) in 0% FBS media for 24 hours. Knockdown of TACE expression in cells was 
achieved through treatments with TACE siRNA (100 nM; Santa Cruz Biotechnology, 
Santa Cruz, CA) for 48 hours according to manufacturer’s protocol. Briefly, 400,000 4T1 
cells were seeded in 6-well plates and incubated for 24 hours in 10% FBS media free of 
antibiotics. Cells were then incubated for an additional 24 hours with TACE siRNA (100 
nM) complexed with Lipofectamine® 2000 (Life Technologies, Grand Island, NY). 
Following washes, cells were incubated with fresh media for an additional 48-hours 
before both cell lysates and supernatants were collected and stored at -20º C.  
Macrophage treatments 
J774 macrophages were incubated with 4T1 tumor cell conditioned media (4T1 
CMs) and their pro-angiogenic properties including the concentrations of VEGF secreted 
determined. Additionally, the role of the NF-ĸB pathway in the pro-angiogenic 
macrophage activities was assessed through pretreatments with the NF-kB inhibitor BAY 
11-7083 (20 µM; Minneapolis, MN, USA) for 30 minutes before stimulation with 4T1 
CMs. Macrophages were also treated with increasing doses of murine MCSF (0-1000 
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ng/mL, BioVision, Milpitas, California, USA) and / or CCL2 (100 ng/mL) for 24 hours 
where indicated. 
Immunoblot analyses 
Protein lysates obtained from tumor cells and macrophages following treatments 
were collected and prepared for immunodetection as described earlier [246,130]. Briefly, 
25 µg of total protein per well were loaded on 8% polyacrylamide gels and separated 
with SDS-PAGE. Proteins were then transferred onto nitrocellulose membranes using a 
semi-dry transfer method. Ponceau S (0.1%, Sigma) staining was performed to determine 
even loading. Membranes were blocked with TBS-T (Tris-buffered saline-0.1% Tween 
20) containing 5% nonfat milk to minimize non-specific binding, then incubated with 
antibodies specific for MCSFR, p-MCSFR, NF-ĸB p65, p-NF-ĸB p65 (Cell signaling, 
Danvers, MA, USA) or β-actin (SigmaAldrich, St Louis, MO, USA). After several 
washes in TBS-T, membranes were incubated with a species-specific horseradish 
peroxidase (HRP) conjugated secondary antibody. Following subsequent washes, a 
chemiluminescent HRP substrate (Pierce, Rockford, IL, USA) was added. Antibody-
bound proteins were detected using a biochemiluminescent imaging system and the 
VisionWork software (UVP, Upland, CA, USA).  Differences in protein expressions 
were evaluated by densitometry using Quantity One software (Biorad, Hercules, CA, 
USA) following normalization to ß-actin expression or to the total unphosphorylated 
protein where indicated. 
Flow-cytometry analyses 
Following detachment using trypsin or scrapping, cells were fixed in 1% 
paraformaldehyde (PFA) and then resuspended in PBS before staining for flow-
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cytometry analyses. TACE surface protein expression was determined as previously 
described [130]. Briefly, after a 10-minunte incubation in 1% bovine serum albumin 
(BSA) solution to prevent non-specific binding, cells were incubated with a TACE 
specific antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 45 minutes at 
room temperature. Following washes, cells were then incubated with a fluorescein 
(FITC) conjugated secondary antibody (Life Technologies, Grand Island, NY, USA). 
Background staining was determined following incubation with the secondary antibody 
alone. Following additional washes, the presence of TACE on the cells was determined 
by flow-cytometry analyses (Fortessa cytometer, Becton Dickinson, San Jose, CA, USA). 
Analyses and graphical representation were obtained using the FlowJo software 
(Ashland, OR, USA). The background associated with the secondary antibody alone is 
displayed on each histogram and data representative of at least three independent repeats 
are presented as percentage of TACE positive cells. 
MCSF and VEGF ELISAs 
MCSF and VEGF levels were assessed using ELISAs conducted following the 
manufacturer‘s recommendations (R&D Systems, Minneapolis, IN, USA). All steps were 
conducted at room temperature. Briefly, plates were coated with either a MCSF or a 
VEGF - specific capture antibody diluted in phosphate buffer saline (PBS) and incubated 
overnight. Following blocking with 1% BSA for 1 hour, CM samples were added and the 
plates were incubated for 2 hours. In a subsequent 2 - hour incubation, MCSF or VEGF -
specific biotin conjugated detection antibodies were added. Following 20 minute 
incubations with the complex streptavidin - HRP, the amount of bound detection 
antibody was detected through the addition of the HRP substrate solution (TMB, Pierce 
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Inc. Rockford, IL, USA). After stopping the reaction with a 2N sulfuric acid (H2SO4) 
solution, the absorbance (450 nm) of each well was determined using a microplate reader 
(Biotek, Winooski, VT, USA) and the concentrations (pg/mL) of MCSF and VEGF 
present in each sample were derived from standards ran along the samples. 
Tube formation assays 
In vitro tube formation assays were performed as described previously [51,52] 
with the following modifications. Briefly, 2H11 cells were seeded at a density of 40,000 
cells per well onto Matrigel
TM
 (San Jose, California, USA) coated 96 well plates. These 
2H11 cell cultures were incubated with specific angiogenic molecules including VEGF 
and / or macrophage CMs. 2H11 cell cultures were incubated at 37°C and 5% CO2 for 9 
hours and the tube formation determined. The presence of tubes was recorded through 
microphotographs (40X magnification) using an IX71 fluorescent microscope equipped 
with a DP70 camera (Olympus, Center Valley, Pennsylvania, USA). The numbers of 
tubes with lengths greater than 100 µm were counted as described earlier and averages 
from at least 3 separate experiments are presented. 
Cytokine arrays 
Cytokine arrays of 4T1 CMs were performed following the manufacturer’s 
recommendations (RayBiotech, Norcross, GA, USA). All steps were performed at room 
temperature. Briefly, membranes were incubated in blocking buffer for 30 minutes. Next, 
following 2 hour incubations with 4T1 CMs, washes, another 2 hour incubation with a 
cocktail of specific biotin-conjugated antibodies, cytokine array membranes were washed 
and incubated with streptavidin - HRP. The HRP activity was detected using a 
chemiluminescent substrate and signal detected using a biochemiluminescent imaging 
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system and the VisionWork software (UVP, Upland, CA, USA). Relative differences in 
protein expressions were evaluated by densitometry using Quantity One software 
(Biorad, Hercules, CA, USA). 
Statistical analyses 
All data were expressed as mean ± SEM unless noted otherwise. Differences 
between parameters tested were determined using one-way ANOVAs and Newmann-
Keul post-hoc tests (Prism, Graphpad Software, Inc., La Jolla, CA, USA). Significance 
was set a priori to p value below 0.05.   
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4.4 Results 
TACE is expressed at higher levels by 4T1 metastatic mammary tumor cells than by less 
invasive carcinoma cells and normal mammary epithelial cells. 
First, the expression of TACE was determined on a panel of murine mammary 
tumor cells and murine epithelial cells. Western blot analyses of protein lysates collected 
from cells demonstrated the presence of TACE. TACE expressions in epithelial cells 
(NMuMG) and non-invasive carcinoma cells (67NR) were lower than TACE expression 
detected in the invasive (4T07) and metastatic (4T1) mammary cells (Figure. 4.1A and 
B). Indeed, 4T1 cells expressed significantly higher levels of TACE compared to 
NMuMG cells (p < 0.05). Moreover, flow-cytometry analyses of the cell-surface 
expression of TACE on mammary tumor cells indicated that 4T1 and 4T07 mammary 
tumor cells were consistently more positive for cell surface TACE expression than 67NR 
cells (Figure. 4.1C).  
MCSF shed through tumor cell TACE activity activates the MCSFR on J774 
macrophages. 
Presence of the TACE substrate MCSF in the supernatants of the mammary 
carcinoma cells tested was measured over time. The MCSF concentration in tumor cells 
peaked after a 48-hour incubation in serum-free media (Figure 4.2A). Following 48-hour 
incubations, as measured by ELISAs on CMs collected from epithelial and mammary 
tumor cells MCSF was not detected in NMuMG CMs. However, MCSF was shed / 
secreted at significantly lower concentrations in CMs from 67NR cells compared to CMs 
from 4T07 and 4T1 carcinoma cells (p < 0.01, Figure 4.2B). Furthermore, the inhibition 
of TACE activities using either treatments with the chemical TACE inhibitor TAPI-0 or 
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with a specific TACE siRNA led to significant decreases in MCSF concentrations present 
in the CMs of 4T1 cells compared to the MSCF concentrations detected in 4T1 CM under 
control conditions (p < 0.05, Figure 4.2C). 
Whether tumor cell TACE-shed MCSF activated MCSFR on J774 macrophages 
was analyzed through Western blots. Macrophages treated with 4T1 CMs and/or MCSF 
(200ng/ml) displayed a significantly higher ratio of the activated MCSFR (pMCSFR) 
normalized to total MCSFR compared to those treated with 4T1 CMs collected after 
TACE inhibition (TAPI-0 4T1 CM) (p < 0.01, Figure 4.2D). Furthermore, macrophages 
treated with TAPI-0 4T1 CMs supplemented with MCSF produced similar levels of 
pMCSFR / MCSFR as those treated with 4T1CMs. 
TACE-shed MCSF from 4T1 cells induces J774 macrophages to secrete VEGF and 
promote endothelial cell tube formation. 
J774 macrophage CMs collected after treatment with tumor cell CM were 
assessed using ELISAs for VEGF and endothelial cell tube formation assays. 
Macrophage VEGF secretions induced by 4T1 CMs were significantly higher than the 
controls and TAPI-0 4T1 CM treatment (p < 0.001, Figure 4.3A). Macrophages treated 
with TAPI-0 4T1 CMs supplemented with MCSF secreted similar concentrations of 
VEGF compared to 4T1 CM treated macrophages. Treatment of macrophages with 100 
ng/mL of MCSF alone stimulated higher VEGF secretions than control conditions (p < 
0.05, Fig 4.3A). However, the concentrations of VEGF secreted were significantly lower 
than the concentrations of VEGF secreted following macrophage incubation with 4T1 
CMs (p < 0.05, Figure 4.3A).  
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CMs collected from macrophages treated with both 4T1 CMs (b) and TAPI-0 4T1 
CM plus MCSF (d) led to significantly higher numbers of tubes in 2H11 tube formation 
assays compared to CMs collected from macrophages incubated with control media (a) or 
TAPI-0 4T1 CM (c) alone (p < 0.001, Figure 4.3B). CMs obtained from macrophages 
treated with MCSF alone (e) did not promote 2H11 tube formation (Figure 4.3C) 
suggesting the presence of at least one additional factor in the tumor CMs that along with 
MCSF promote macrophages with pro-angiogenic properties. In contrast, addition of 
increasing VEGF concentrations to endothelial cells (f and g) led to a dose-dependent 
increase in 2H11 tube formation (Figure 4.3C). 
The stimulation of macrophage NFkB signaling pathway by tumor cell TACE-shed 
MCSF is essential to the pro-angiogenic properties of macrophages. 
Next, activation of the NFκB signaling pathway, critical in tumorigenesis, was 
investigated in macrophages. Macrophage pNFkB p65 / NFĸB p65 ratios were 
significantly increased by treatment with total 4T1 CMs but not TAPI-0 treated 4T1 CMs 
as compared to control conditions (p < 0.05, Figure 4.4A). The increased pNFkB p65 / 
NFĸB p65 levels were rescued by supplementing TAPI-0 4T1 CM treated macrophages 
with MCSF (Figure 4.4A). Additionally, treatment of macrophages with the NFĸB 
pathway inhibitor BAY 11-7083 significantly diminished macrophage VEGF secretion 
following incubation with 4T1 CMs (p < 0.001, Figure 4.4B). Furthermore, the number 
of 2H11 tubes formed decreased following incubation of 2H11 cells with CM collected 
from BAY 11-7083 inhibited tumor cell CM treated macrophages (p < 0.05, Figure 
4.4C).  2H11 tube formation was rescued by adding VEGF to BAY 11-7083 inhibited 
macrophage CMs (Figure 4.4C). Interestingly, whereas MCSF along with tumor 
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secretions promoted activation of NFĸB, MCSF alone had no effect on NFĸB activation. 
Taken together with observations that macrophage VEGF secretions and tube formation 
are significantly lower in MCSF stimulated macrophages compared to 4T1 CM 
stimulated macrophages (Figure 4.3) strongly suggest the presence of other factor(s) in 
the 4T1 CMs cooperating with MCSF to activate NFĸB, stimulate VEGF production and 
promote angiogenesis. 
Malignant mammary cells secrete significantly higher levels of CCL2 compared to 
mammary epithelial cells which is not affected by TACE inhibition. 
High CCL2 expression was detected in 4T1 CMs as evaluated in cytokine arrays 
(Figure 4.5A). Furthermore, significantly higher CCL2 concentrations were secreted by 
malignant mammary cells (4T1, 4T07 and 67NR) compared to normal mammary 
epithelial cells (NMuMG) (p < 0.05, Figure 4.5B). Regardless of the cells tested, 
following treatment with TAPI-0, secreted CCL2 concentrations remained unchanged 
(n.s., Figure 4.5B). 
TACE-shed MCSF and secreted CCL2 by tumor cells induce pro-angiogenic 
macrophages through the activation of MCSFR. 
J774 macrophages treated with the combination of CCL2 and MCSF secreted 
significantly higher concentrations of VEGF than when treated with MCSF alone (p < 
0.05, Figure 4.6A). Furthermore, compared to the CMs from macrophages treated with 
MCSF or CCL2 alone, the CMs collected from macrophages treated with the 
combination CCL2 and MCSF lead to significantly higher 2H11 tube formations 
(p<0.001, Figure 4.6B). In contrast, endothelial cells incubated with MCSF or CCL2 
alone, at the same concentrations used for macrophage treatments, had no direct effects 
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on tube formation (n.s., data not shown). The number of 2H11 tubes formed by 
macrophage CMs collected following incubation with CCL2 was similar to the number of 
2H11 tubes formed following incubation with macrophage CMs collected following 
incubation with TAPI-0 4T1 CMs (Figure 4.6B). Moreover, macrophage CMs collected 
following incubation with CCL2 and MCSF led to similar 2H11 tube formations as 
macrophage CMs collected following incubation with 4T1 CMs (Figure 4.6B). 
Macrophage pNFkB p65 / NFĸB p65 protein expression ratios were significantly 
increased by treatment with MCSF and CCL2 alone compared to pNFkB p65 / NFĸB p65 
protein expression ratios in macrophage incubated in control conditions (p < 0.05, Figure 
4.6C and D). Furthermore, following treatment with the combination MCSF and CCL2, 
macrophage pNFkB p65 / NFĸB p65 protein expression ratios were significantly higher 
than when incubated with either cytokine alone (p < 0.05, Figure 4.6C and D). 
Next, to determine whether CCL2 synergized with MCSF through increased 
activation of the MCSFR, levels of activated MCSFR in macrophages incubated with 
CCL2 and MSCF were assessed. Macrophages treated with MCSF alone but not with 
CCL2 alone expressed significantly higher pMCSFR / MCSFR protein ratios compared 
to macrophages incubated in control conditions (p < 0.05, Figure 4.7A and B). Moreover, 
macrophages incubated with the combination MCSF and CCL2 expressed significantly 
higher pMCSFR / MCSFR protein ratios compared to macrophage incubated with any 
other conditions tested (p < 0.05, Figure 4.7A and B).  Furthermore, a dose-dependent 
increase of the pNFkB p65 / NFĸB p65 protein expression ratio was observed in 
macrophages incubated with increasing MCSF (0-1000 ng/ml) concentrations (Figure 
4.7C). However, since the concentrations of MCSF shed by macrophages treated with 
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increasing doses of CCL2 (0-1000 ng/ml) remained unchanged (Figure 4.7D), CCL2 
likely does not promote an autocrine MCSF loop in macrophages. 
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4.5 Discussion 
TAMs are critical regulators of the tumor vasculature [41] and in some areas of 
the tumor the principal producers of the potent angiogenic factor, VEGF [276]. Tumor-
derived MCSF shed through TACE activities, and secreted CCL2 both stimulate 
macrophage production of VEGF [264,261,266]. The role of VEGF released from TAMs 
in promoting breast tumor angiogenesis is well established; however, the specific 
pathways involved remain elusive and anti-VEGF therapies lack effectiveness in the 
treatment of breast cancer [271]. Here using in vitro models, we demonstrate that (1) 
TACE, MCSF and CCL2 expressions are increased in invasive and metastatic mammary 
carcinoma cells and that (2) tumor cell TACE-shed MCSF activates the NF-κB associated 
signaling pathway in macrophages stimulating the secretion of VEGF which in turn leads 
to endothelial cell tube formation. Furthermore, our observations indicate that 4T1 cell 
TACE-shed MCSF together with secreted CCL2 promote the generation of pro-
angiogenic macrophages. Taken together we propose a model in which breast tumor cell 
shed MCSF and secrete CCL2 stimulate pro-angiogenic macrophages through NF-κB 
(Figure 4.8).  
In vitro models have been utilized extensively to advance our understanding of 
the complex cell-cell interactions occurring within the tumor microenvironment in both 
2D and 3D cultures conditions [10,277]. In particular, previous works have revealed a 
critical interplay between tumor derived factors such as MCSF and CCL2, leading to the 
promotion of pro-tumor macrophages [73,130]. Additionally, the roles of stromal cells, 
including macrophages and mesenchymal stem cells, in the formation of mammary gland 
structures, such as blood vessels and acini, have been identified [277,11,54]. The 
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fundamental processes and pathways exposed using in vitro models has greatly enhanced 
our understanding of breast tumorigenesis [278]. 
In the present study, TACE was expressed at higher levels in invasive and 
metastatic murine mammary carcinoma cells supporting previous observations in human 
breast tumors [7,91].  Indeed, increased TACE expression in the tumors of breast cancer 
patients correlates to decreased survival [7]. Our observations further indicate that the 
TACE activities in tumor cells led to the shedding of multiple molecules including 
MSCF, which through paracrine interactions with macrophages promoted the stimulation 
of pro-tumor TAMs. This observation is in line with the previously identified role of 
tumor cell TACE shedding in blunting macrophage responses to the anti-tumor 
macrophage stimulator TNF [130]. In addition to paracrine signaling in tumors, TACE 
activities also strongly influence autocrine signaling. Indeed, tumor cell TACE shedding 
led to autocrine activation of EGFR and stimulated the mitogen-activated protein kinase 
(MAPK) signaling pathway resulting in a malignant phenotype of tumor cells [7]. 
Identifying the multiple TACE substrates cleaved from tumor cells involved in paracrine 
and autocrine pro-tumor activities may provide more specific targets for cancer treatment. 
Additionally, the non-shedding activities of TACE including adhesion through the 
disintegrin domain [279] and signaling through the cytoplasmic tail [280] may also be 
critical in breast cancer progression. 
This study indicated that increases in soluble MCSF concentrations correlated to 
TACE expression and were higher in metastatic cancer cells. Others have shown MCSF 
response gene expressions to be associated with poor prognostic factors including high 
tumor grade, decreased expression of estrogen receptor / progesterone receptor and 
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increased p53 mutations in breast cancer patients [64]. Here, MCSF a key regulator of 
macrophages and of TAM functions [42,281] produced through tumor cell TACE 
shedding stimulated pro-angiogenic macrophages. Our observations indicated that 
MCSF, through macrophage MCSFR activation, led to the release of VEGF and to 
subsequent increases in endothelial cell tube formation highlighting the pivotal role of 
MCSF in promoting breast tumor angiogenesis through activation of macrophages 
[41,276]. These results confirm previous works that demonstrated MCSF induced release 
of VEGF from primary human monocytes [282] and that MCSF deficient mice have 
decreased TAMs abundance and subsequent diminished tumor vasculature [41]. 
The promotion of a pro-angiogenic macrophage phenotype through tumor cell TACE-
shed MCSF was shown here to be dependent on NF-ĸB signaling. Indeed, NF-ĸB 
inhibition prevented the tumor stimulated macrophage release of VEGF and 2H11 tube 
formation. In macrophages, NF-ĸB is a central transcription factor involved in the 
activation of both pro- and anti-tumor genes [283-285]. MCSF derived from the 
metastatic human breast cancer MDA-MB-231 cells induced NF-ĸB signaling in 
RAW264.7 murine macrophages, which in turn caused release of nitric oxide to promote 
MDA-MB-231 tumor cell invasion [73]. Moreover, the stimulation with recombinant 
MCSF of macrophages led to VEGF production that was dependent on extracellular 
regulated kinase (ERK) signaling [266]. Additionally, the polarization of pro-tumor 
macrophages has been shown to be dependent on signal transducer and activator of 
transcription (STAT) signaling [283,286]. Together these data strongly suggest that 
multiple pathways, especially NF-ĸB, in TAMs likely cooperate to promote tumor 
angiogenesis. 
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Interestingly, the effects of 4T1 CM on the generation of pro-angiogenic 
macrophages could be reproduced using the combination of MCSF and CCL2. Indeed, 
here the formation of tubes by 2H11 murine endothelial cells was sensitive to VEGF 
released by macrophage stimulated with MCSF and CCL2. This is in contrast with 
human umbilical vein endothelial cells (HUVECs), which form tubes mainly in response 
to VEGF released by MCSF stimulated macrophages [282] and lack the ability to 
respond to other angiogenic factors, including interleukin 8 (IL-8) [287]. However, our 
findings are comparable to observations made in melanoma in which MCSF and CCL2 
act together to promote macrophage VEGF release [288]. Whether the difference in 
sensitivity of macrophages and subsequent VEGF secretion may explain the 
ineffectiveness of anti-VEGF inhibitors in the treatment of melanoma [289] and breast 
cancer [271] remains to be fully investigated. 
Taken together, these findings validate the role of MCSF shed from breast cancer 
through TACE activities and highlight the critical cell-cell interactions within the tumor 
microenvironment. The specific pathway identified here through which tumor cell 
TACE-shed MCSF activates NF-κB in macrophages leading to VEGF release and 
subsequent 2H11 tube formations (see figure 4.8) underlines potential targets including 
TACE, MCSF and CCL2 that if locally targeted and specifically inhibited alone or 
together may prevent TAM stimulated angiogenesis in breast cancer. 
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4.6 Figures 
 
 
 
 
Figure 4.1. TACE expression is increased in metastatic mammary tumor cells. (A) 
Representative immunoblots of the TACE expressions in NMuMG epithelial cells, 67NR, 
4T07 and 4T1 murine mammary carcinoma cells (level of aggressiveness denoted by 
gradient). ß-actin expression served as loading control. (B) Quantification of TACE 
expression normalized to ß-actin in epithelial and carcinoma cells indicates that 
metastatic 4T1 cells express significantly higher levels of TACE compared to NMuMG 
epithelial cells (p < 0.05). (C) TACE expression assessed by flow-cytometry. The 
background (shaded area) is defined by the non-specific binding associated with the use 
of the secondary antibody alone. The cell-surface expression of TACE (open area) by 
4T07 and 4T1 murine mammary carcinoma cells was higher than the expression detected 
in 67NR cells. The observations presented are representative of 3 or more independent 
repeats.  
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Figure 4.2. MCSF-shed through mammary tumor cell TACE activities is blocked by 
either a TACE inhibitor (TAPI-0) or TACE siRNA and promotes the activation of 
MCSFR on J774 macrophages. (A) By ELISAs, the highest concentrations (pg/ml) of 
MCSF were observed in supernatants collected over time from 4T1 (filled bars) and 4T07 
cells (open bars) after 48-hour incubations. (B) Concentrations of MCSF determined by 
ELISA in CMs harvested following a 24-hour serum starvation / treatment period and a 
48-hour incubation with phenol red free RPMI demonstrate that 4T07 and 4T1 cells shed 
significantly higher concentrations of MCSF than 67NR and NMuMG cells (p < 0.01). 
(C) Incubation of 4T1 cells with either the TACE inhibitor (TAPI-0; 250 nM) or a TACE 
specific siRNA (100 nM) lead to significant decreases of shed MCSF compared to 
control conditions (p < 0.05). (D) Immunoblots of protein lysates from J774 macrophages 
incubated with 4T1 tumor CMs and / or MCSF indicates that 4T1 CMs but not 4T1 
incubated with TAPI-0 CMs promoted the activation of MCSFR leading to a higher 
pMCSFR / MCSFR ratio (p < 0.01). Moreover, the 4T1 incubated with TAPI-0 CMs 
supplemented with MCSF also increased pMCSFR / MCSFR ratio in J774 cell lysates (p 
< 0.01).  
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Figure 4.3. 4T1 mammary tumor cell TACE-shed MCSF stimulates the secretion of 
VEGF by J774 macrophage and induce endothelial cell tube formation. (A) Following 
incubation with tumor CMs and / or MCSF, concentrations of VEGF secreted by J774 
macrophages were determined by ELISAs. Both 4T1 CMs and TAPI-0 4T1 CMs plus 
MCSF treatments promoted significantly higher VEGF secretions by macrophages 
compared to incubations with TAPI-0 4T1 CMs alone or control media alone (p < 0.01). 
Also, macrophages treated with 4T1 CMs secreted significantly higher concentrations of 
VEGF than those treated with MCSF only (p < 0.05). (B) The capacity of these 
macrophage CMs to promote 2H11 endothelial cell tube formation in Matrigel
® 
was 
determined. Representative microphotographs of 2H11 tubes after treatments are 
provided (bar = 400 µm). CMs from macrophages treated with 4T1 CMs and TAPI-0 4T1 
CMs plus MCSF promoted significantly higher numbers of tubes than TAPI-0 4T1 CMs 
and control media treated macrophages (p < 0.001). No tubes were observed with CM 
from macrophages treated with MCSF alone. VEGF promoted tube formation in a dose 
dependent manner. 
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Figure 4.4. MCSF-shed by mammary tumor cell promotes NF-kB signaling in 
macrophages leading to the secretion of factors promoting endothelial cell tube 
formation. (A) Representative immunoblots of pNFĸB p65, NFĸB p65 and β actin 
expressions by J774 macrophages following incubations with MCSF, 4T1 CMs and / or 
4T1 CMs collected following TAPI-0 treatments. (B) The ratio of pNF-ĸB p65 / total 
NF-ĸB p65 protein expression in J774 macrophages increased significantly following 
incubation with 4T1 CMs and TAPI-0 4T1 CMs plus MCSF treatments (p < 0.05). (C) 
VEGF concentrations present in the supernatants collected from J774 macrophages 
incubated with 4T1 tumor CMs were higher than in in the supernatants collected from 
J774 macrophages incubated without 4T1 tumor CMs (p < 0.01).  Moreover, the 
supplementation of macrophages incubated with 4T1 tumor CMs with the NF-kB 
inhibitor (BAY 11-7083) inhibited that VEGF secretion. (D) Furthermore, secretions 
from macrophages treated with 4T1 CM promoted significantly higher 2H11 cell tube 
formation than control media treated macrophages (p < 0.05), whereas 4T1 treated 
macrophage CMs collected following NK-kB inhibitor treatment (BAY 11-7082) lead to 
significantly lower 2H11 tube formation. This decrease in 2H11 tube formation could be 
restored through VEGF supplementation (p < 0.05). Scale bar = 200 µm. 
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Figure 4.5. CCL2, highly expressed by 4T1 cells is secreted significantly more by murine 
tumor cells than by normal murine epithelial cells. (A) Among the inflammatory 
cytokines secreted by 4T1 cells as assessed using semi-quantitative protein arrays, CCL2 
is highly expressed. (B) As determined by ELISA, concentrations of secreted CCL2 were 
significantly higher in the supernatants collected from malignant breast cells compared to 
the supernatants collected from normal breast epithelial cells (NMUMG). Following 
treatment with the TACE inhibitor TAPI-0 (filled bar) cells yielded similar CCL2 
secretions regardless of the cells tested compared to cell incubated with the vehicle 
treatment (DMSO; open bar). 
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Figure 4.6. The combination of 4T1 tumor cell TACE-shed MCSF, 4T1 tumor cell 
secreted CCL2 promotes the macrophage secretion of VEGF and 2H11 endothelial cell 
tube formation. (A) J774 macrophages incubated with the combination MCSF (100 
ng/ml) and CCL2 secreted higher VEGF concentrations than J774 cells incubated with 
MSCF alone. (B) Supernatants from macrophages treated with 4T1 CM, TAPI-0 4T1 CM 
plus MCSF, and MCSF plus CCL2 promoted significantly higher 2H11 endothelial cell 
tube formation than supernatants from macrophages treated with TAPI-0 4T1 CM, MCSF 
and CCL2 treatments alone (p < 0.001; Scale bar = 400 µm). (C) Representative 
immunoblots of pNFĸB p65, NFĸB p65 and β actin expressions by J774 macrophages 
following treatment with MCSF (200 ng/ml) and/or CCL2 (D) The ratio of pNF-ĸB p65 / 
total NF-ĸB p65 protein expression in J774 macrophages was significantly increased 
following incubation MCSF (200 ng/ml) or CCL2 alone (p<0.05). Furthermore, treatment 
with the combination MCSF and CCL2 led to an even higher pNF-ĸB p65 / total NF-ĸB 
p65 protein expression ratio in J774 macrophages (p < 0.05) 
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Figure 4.7. MCSF and CCL2 combined activation of J774 macrophage MCSFR. (A) 
Lysates from J774 macrophages incubated with MCSF or the combination MCSF and 
CCL2 expressed significantly higher pMCSFR / MCSFR ratios as shown in 
representative Western Blots. (B) Quantification of the pMCSFR / MCSFR ratios 
confirmed that J774 macrophages incubated with MCSF or the combination MCSF and 
CCL2 expressed significantly higher pMCSFR / MCSFR ratios compared to J774 cells 
incubated in control conditions (p < 0.05 and p < 0.01 respectively). (C) J774 
macrophages incubated with increasing MCSF concentrations (0-1000 ng/ml) expressed 
dose-dependent increases in pNF-ĸB p65 / total NF-ĸB p65 ratios as shown in 
representative Western blots. (D) However, MCSF concentrations in the CM collected 
from J774 macrophages treated with increasing CCL2 concentrations (0-1000 ng/mL) 
remained unchanged 
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Figure 4.8. Proposed mechanism of the activation of pro-angiogenic macrophages by 
breast carcinoma cell TACE-shed MCSF. Tumor cells through TACE shedding of MCSF 
and secretion of CCL2 promote activation of the NF-κB signaling pathway in 
macrophages, which in turn secrete VEGF. The secretions of VEGF from these 
macrophages promote angiogenesis. Tumor CM stimulated release of VEGF and 
promotion of angiogenesis by macrophages can be blocked by inhibiting TACE (TAPI-0) 
on tumor cells or NF-κB (BAY 11-7083) in macrophages. 
  
 
CHAPTER 5: CONCLUSION AND FUTURE DIRECTIONS 
 
 
Breast cancer remains the most prevalent malignancy in women and among the 
most deadly [290]. The emergence of the tumor microenvironment as a major contributor 
to the progression and metastatic spread of cancer [5] highlights the need for a further 
understanding of the mechanisms and molecules involved in the promotion of a pro-
tumor microenvironment. In particular, elucidating how TAMs are activated to express 
primarily pro-tumor characteristics rather than tumor cytotoxic activities may reveal 
factors and pathways that, through treatment, may skew TAMs towards an anti-tumor 
phenotype. At specific locations within tissues, the activation of the macrophage 
phenotype activation is defined by the presence and activities of immunomodulatory 
factors that promote changes in macrophage recruitment and macrophage protein 
expression. Therefore, the aim of my dissertation was to investigate the role of tumor cell 
TACE activities in modulating pro-tumor macrophage functions through the 
immunomodulatory substrates it releases, chiefly TNFRs and MCSF. 
The primary downstream events activated by TNF and MCSF are migration and 
phenotype activation, respectively; therefore, we investigated the effects of TACE 
shedding on these macrophage activities. Our data show that the chemotaxis of 
macrophages towards the anti-tumor (M1) stimulus TNF was diminished by tumor-shed 
TNFRs. We also provide evidence that the ability of macrophages to promote 
angiogenesis, an M2 characteristic, is mediated in part by TACE-shed MCSF. Taken 
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together, these results highlight the importance of tumor cell TACE activities in the 
generation of pro-tumor macrophages and underline potential therapeutic targets for the 
treatment of cancer. Identifying additional TAM activities altered by tumor cell 
TACEshedding activities will deepen our understanding of pro-tumor macrophages 
functions. For example, shed VCAM1 alters monocyte adhesion to the endothelium, a 
critical step in TAM recruitment, in RCC whereas shed TGFα drastically modifies 
macrophage proliferation in leukemias [199,140]. Recently, shedding of IL6R has been 
shown to amplify IL6 signaling, a critical signaling pathway involved in macrophage 
recruitment and M2 phenotype activation in wound settings and numerous cancers 
[212,23,152]. Thus, a molecular understanding of the role of TACE-shedding and TACE 
shed molecules signaling alone or in combination [291] in modulating TAM activities at 
the tumor site is needed to improve the use of TACE inhibition to treat breast cancer. The 
observations made here participate in deciphering the effects of TACE shedding in 
modulating TAMs migration and angiogenesis. The investigated effects of TACE 
shedding on macrophage migration and phenotype and proposed effects on TAMs 
adhesion, apoptosis, matrix remodeling abilities are diagramed in Figure 5.1 and the 
specific effects that have been demonstrated are outlined in Table 5.1. The macrophage 
functions that are altered by TACE shedding will depend on the concentrations and 
activities of the factors (outlined in Table 2.2) present. 
The cell-cell interactions studied here are complex and more suitably analyzed 
using in vitro models [305,306]. The 4T1 murine mammary cancer progression series 
includes the 4T1, 4T07 and 67NR cells which model metastatic, invasive and benign 
breast cancer, respectively (outlined in Table 5.2) [307]. This mammary cancer series 
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summarizes breast cancer progression stages and allows the comparison of the relative 
expression of TACE and its substrates during various stages of breast cancer progression 
[308]. The benefits and limitations of this approach have been detailed elsewhere 
[307,308]. The use of the 4T1 murine mammary series was dictated by the need for 
immunological compatibility with J774 and RAW macrophages also derived from Balb/c 
mice [309,310,311]. Whether the present results can be extended to other mammary 
tumor cells and breast cancer progression series remains to be determined. Although 
multiple human mammary cell lines are available to verify the observations made here in 
a murine mammary tumor progression series [312,313], analyses of macrophages tumor 
cell interactions remains limited by the available macrophage cells. Nevertheless, 
carrying out these experiments is essential to validate the role of tumor cell TACE-shed 
molecules in the generation of a macrophage driven pro-angiogenic environment.   
Changes in macrophage functions, such as adhesion and apoptosis, were expected 
to result from tumor cell TACE shedding [292]. Our recent (unpublished) experiments 
using in vitro approaches tested whether tumor cell TACE shedding impacts the 
apoptosis of macrophages. The data indicates that tumor cell TACE shed factors 
significantly promote J774 and RAW macrophage apoptosis as shown through nuclear 
condensation and caspase activity assays (Figure 5.2). Although the TACE shed factor(s) 
responsible for promoting macrophage apoptosis remains to be identified, other studies 
have shown that shed Fas ligand (FasL) and / or sTNFRs promote macrophage apoptosis 
[293-295]. Therefore, future studies on the mechanisms involved in the apoptosis of 
macrophages observed here will assess the role of shed Fas ligand (FasL) and / or 
sTNFRs in macrophage apoptosis through studies using macrophages treated with CM 
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from tumor cells collected after siRNA knockdown or neutralizing antibodies for FasL or 
TNFRs. Studies determining that FasL and/or TNFRs recapitulates the effects of TACE 
inhibition and rescuing the apoptosis promotion through using supplementation of TACE 
inhibited CM with FasL and / or TNFRs would further indicate the key role of FasL or 
TNFRs in the regulation of macrophage apoptosis. Moreover, determining whether tumor 
induction of macrophage apoptosis is selective, i.e. specific to M1 macrophages, is 
critical and would provide an alternate explanation for the presence of primarily M2 pro-
tumor population of TAMs. 
Additionally, our data (unpublished) indicates that tumor cell TACE shedding is 
important in macrophage adhesion. The adhesion of macrophages to endothelial cells is 
an essential step in recruitment to cancerous or inflamed tissue [39]. Numerous tumor-
shed TACE substrates, including VCAM1, MCSF and ICAM1, have dramatic effects on 
macrophage adhesion. Thus, our studies defined the effects of TACE shedding on 
macrophage adhesion to the endothelium. In experiments measuring the adhesion of 
macrophages to an endothelial cell monolayer under various conditions, macrophages 
treated with tumor-shed factor had a significantly higher adhesion to endothelial cells in 
vitro (Figure 5.3). Further, the macrophage adhesion to 2H11 endothelial cells stimulated 
by tumor cells TACE shedding was dependent on lectin-binding as indicated by the 
decreased adhesion observed following pretreatment with the α-D-mannosyl and α-D-
glucosyl residue inhibitor, Concavalin A (Con A) (Figure 5.3, p < 0.05). Current 
experiments aim to identify the specific tumor cell TACE-shed substrate associated with 
increased macrophage adhesion and determine whether inhibiting TACE translates to 
decreased macrophage adhesion and infiltration in vivo. These observations along with 
95 
the results outlined in Chapters 3 and 4 provide strong evidence for the role of TACE 
activities on macrophage recruitment, survival and M2 activation. 
Aside from anti-angiogenic treatments, no other approved therapies exist that effectively 
target the non-malignant cellular component of the tumor microenvironment [289,269]. 
Although effective in many cancers including glioblastoma [296], colorectal cancer 
[297], renal cell carcinoma [298] and non-small cell lung cancers [299] anti-angiogenic 
treatments have failed to extend overall survival in breast cancers patients [300]. This is 
likely due to other mechanisms supporting vasculogenesis especially vascular mimicry 
which has been shown to play a critical role in breast cancer and melanoma and appear to 
have no or a more limited effects in other cancers [314,315]. Our studies, along with 
others [85,70,41,20,43], provide evidence that targeting macrophages or pro-tumor 
macrophage functions could benefit breast cancer patients. TAMs support many pro-
tumor functions including promotion of tumor cell invasion and matrix remodeling, 
immune-suppression, chemo-resistance and angiogenesis as confirmed here. Identifying 
methods to reduce the presence of TAMs at the tumor site or reverse their pro-tumor 
activation has the potential to inhibit tumor progression at numerous stages as well as 
improve the effectiveness of chemotherapies [301,15]. Our results indicate that TACE 
inhibition promotes macrophage response to anti-tumor stimuli and diminishes pro-
tumor, angiogenic, TAM activation. Thus, inhibiting TACE at the tumor site to target 
TAMs may promote cytotoxic macrophages and diminish angiogenesis. Understandably, 
targeting a nonmalignant cells, such as macrophages, must be done with care as 
macrophages are vital to the normal physiologic processes, including response to 
pathogens, wound healing and organ development [38,302,118,66]. However, with 
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evidence that pro-tumor macrophages are observed in every subtype of breast cancer the 
use of TAM targeted therapies as a tool to overcome tumor heterogeneity remains 
extremely attractive. Therefore, rather than systemic depletion or inactivation of 
macrophages, approaches promoting tissue-specific reduction, depletion and / or 
redirecting the activation of breast tumor TAMs toward M1 like phenotype may lead to 
significant changes in breast cancer progression with limited side-effects. Current 
targeted cancer therapies using antibody conjugates or loaded nanoparticles [170,47,95] 
combined with specific TACE inhibitors to treat breast cancers may prove to be a 
clinically relevant approach.  
TACE activation has been demonstrated previously to have pro-tumor effects in 
breast cancer through the stimulation of tumor cell growth and invasiveness following 
autocrine release of GFs [7]. Our data demonstrate some of the indirect effects of tumor-
TACE-shed factors on pro-tumor TAMs (Figure 5.3). Taken together, these studies 
indicate the use of TACE inhibitors for the treatment of breast cancer may have 
beneficial effects by directly blocking GF signaling in tumors and diminishing pro-tumor 
TAM presence and functions. In vivo studies will assess the impact of TACE inhibitors 
on tumor growth as well as TAM abundance and phenotype and verify whether this 
treatment approach will translates into extended disease-free and overall survival. Little is 
known regarding the regulation of TACE. However, TACE activity is stimulated rapidly 
in response to inflammatory and growth factor signaling molecules through processes 
involving the extracellular catalytic domain of TACE [316]. Current inhibitors including 
TAPI-0 prevent TACE activities by irreversibly binding to the catalytic domain of TACE 
[316]. 
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As shown here the inhibition of the tumor-shed TACE substrates, cytokine 
receptors TNFRs and cytokine MCSF, drastically altered macrophage functions. Thus 
approaches targeting TNFRs and MCSF signaling pathways will likely generate more 
tailored effects on macrophages than the direct inhibition of TACE activities. As 
indicated in chapter 2, tumor cell shedding of TNFRs is a mechanism by which tumors 
inhibit the response of macrophages to TNF [293]. Accordingly, if sTNFRs were 
sequestered or TACE activation inhibited, TNF may stimulate tumor cell death directly 
as well as indirectly through the activation of M1 cytotoxic macrophages. This likely 
would result in the presence of activated macrophages at the tumor site that could better 
engulf and destroy tumor cells. In the present studies, the respective contributions of the 
shedding of TNFR1 and of TNFR2 were not investigated as shedding of sTNFR2 was 
increasing with the aggressiveness of the mammary tumor and as blocking specifically 
the sTNFR2 strongly affected the TNF signaling. However, a contribution of the sTNFR1 
cannot be excluded by the data presented here. Alternatively, one could potentially 
administer TNF into the breast tumor mass preventing its diffusion to other tissues, at a 
dose that ensures its effects on macrophage activation aren’t hampered by sequestration 
with sTNFRs. Thus far, the use of TNF for the treatment of cancers has been largely 
ineffective due to tumor intrinsic mechanisms to prevent its apoptotic effects [236,28] 
such as the mechanisms presented here and the overall toxicity and side-effects of TNF 
treatments [28,303]. Nonetheless, it remains to be determined whether sequestration of 
sTNFRs leading to TNF induced M1 macrophages alone would promote tumor 
regression in breast cancer patients.  
98 
Targeting MCSF, the other TACE substrate identified in our studies, to promote 
pro-tumor macrophages may also have beneficial effects. Blocking MCSF at the tumor 
site would decrease multiple pro-tumor TAM activities. Here we demonstrate that MCSF 
in the context of other tumor-derived factors significantly contributes to the promotion of 
angiogenic macrophages. Others have demonstrated that TAMs are essential stimulators 
of angiogenesis in tumors going as far as to coin them the controllers of the “angiogenic 
switch” [41]. Therefore, inhibiting MCSF may decrease breast tumor angiogenesis 
through decreased TAM activation. It should be pointed out that the studies done here 
indicated that MCSF alone was not sufficient to promote angiogenesis alone. Whether 
blocking MCSF signaling in macrophage depleted versus control tumors leads to 
alteration in angiogenesis assessed through the number of blood vessels present remains 
to be determined. Others have demonstrated an important role of MCSF in reciprocal 
tumor cell-macrophage signaling which guides the process of tumor cell streaming and 
results in the invasion and intravasation of breast tumor cells into the blood stream [122]. 
Thus, inhibiting MCSF may also interfere with tumor cell streaming effectively 
disrupting the ability of breast tumor cells to metastasize.  
The ability of tumor shed MCSF to stimulate macrophage angiogenesis was 
reliant on the presence of CCL2 in the tumor CM as demonstrated in chapter 3. Clinical 
studies have drawn attention to the fact that inhibiting a single factor is often never 
sufficient to successfully treat the advanced stages of breast cancer [304]. Although the 
use of combination therapies is increasing, very few targeted combination inhibitors are 
currently available in part due to lack of understanding of the cell and molecular 
combined effects of multiple molecules. Our studies indicated that blocking TACE 
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shedding of MCSF alone resulted in residual angiogenic activity in macrophages 
compared to controls, which exhibited no angiogenic activities. This residual angiogenic 
activity was associated with tumor secreted CCL2 activities. Further, the dual inhibition 
of MCSF and CCL2 prevented the generation of pro-angiogenic macrophages when 
compared to treatment inhibiting MCSF alone (Figure 5.1). In addition to the combined 
direct inhibition of MCSF and CCL2, other targets may be identified by further analyses 
of synergism mechanisms between these factors. Indeed, the cooperative effects of 
MCSF and CCL2 in stimulating angiogenic macrophages appear to be guided by 
crosstalk between the MCSFR and CCR2 on macrophages. Furthering our understanding 
of the interactions between CCL2 and MCSF in the activation of pro-angiogenic 
macrophages including defining whether the effects of MCSF and CCL2 are additive or 
synergistic is crucial for the development of effective and targeted inhibitors. 
Just as the appreciation for the heterogeneity in breast cancers has led to divergent 
treatment strategies for the different cancer subtypes, therapies targeting TAMs for the 
treatment of breast cancer may follow a similar trend. Patients whom benefit the most 
from TAM targeted therapy, such as TACE inhibition, will likely be those with high 
levels of TAM infiltration and M2 phenotype markers. Since the majority of breast 
cancer patients exhibit high levels of TAMs the patient population eligible and potentially 
responsive to anti-TAM therapy is large [64,22]. Targeting the microenvironment is one 
approach to overcome tumor heterogeneity as increased angiogenesis and TAM 
abundance are observed in breast and other cancers [64,41]. However, the assessment of 
therapies directed against the nonmalignant tumor microenvironment remains difficult. 
Aside from the clinical parameters (disease-free and overall survival) and measuring the 
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tumor burden, measures of the treatment efficacy, the use of therapies targeting the tumor 
microenvironment either alone or in combination with tumor directed therapies may 
require additional assessment tools including the determination of TAM abundance and 
phenotype or vascular density within the tumor mass.  
 In summary, our results indicate that molecules shed by TACE from tumor cells 
significantly alter macrophage functions including recruitment, survival and activation 
through various mechanisms (Figure 5.1). These results obtained in vitro using a well-
defined mammary tumor progression series need to be confirmed in human breast cancer 
specimens. Overall, our data highlight the key role of the tumor microenvironment in 
essential steps of breast tumor progression, further our understanding of the tumor cell – 
macrophage – endothelial cell interactions within the tumor mass and suggest new 
treatment strategies that may benefit breast cancer patients. 
101 
5.2 Figures 
 
 
 
 
 
 
Figure 5.1. Multiple mechanisms associated with TACE shedding by tumor cells in 
modulating macrophage functions. The red highlights the contribution of the present 
work to our understanding of those mechanisms. 
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Figure 5.2. Macrophage apoptosis and caspase activation following treatment with tumor 
CMs. (A) RAW macrophages were treated with different concentrations of 4T1 tumor 
CMs collected following incubation in media (4T1 CM) or in media + TAPI-0 (TACE 
inhibitor; 4T1 + TAPI-0 CM) and the % of apoptosis determined. Briefly, cells were were 
stained with the vital nuclear dye (Hoerchst) and number of condensed nuclei counted 
and normalized to total number of nuclei. 4T1 CM (1:1) promoted significantly higher 
levels of macrophage apoptosis compared to all other treatment groups (p < 0.01). (B) 
Caspase 3/7 activities were assayed in lysates collected from RAW macrophages after 
treatment with varying concentrations of 4T1 tumor cell 4T1 CM or 4T1 + TAPI-0 CM. 
Similarly, macrophages treated with 4T1 tumor cell CMs (1:1) had at least a 15-fold 
higher caspase activity compared to all other treatment groups tested (p < 0.01). 
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Figure 5.3. Macrophage adhesion to a 2H11 endothelial layer following treatments with 
4T1 tumor CMs and / or lectin inhibitors. The adhesion of fluorescently labeled J774 (A) 
and RAW (B) macrophages to an endothelial cell monolayer in the presence of different 
4T1 tumor cell CMs was measured after 1 hour. The adhesion is expressed in relative 
fluorescence unit [RFU arbitrary units] following removal of unattached cells. .Adhesion 
of J774 (C) and RAW (D) macrophages was measured following treatments with tumor 
CMs alone or with the lectin inhibitor concavalin A (Con A). In all experiments 
macrophage adhesion was significantly enhanced by total tumor CM compared to all 
other treatment groups (p < 0.05). 
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TABLE 5.1. Effects of TACE substrates on macrophage functions 
 
 
Macrophage  
Function 
Effect Substrate(s) 
involved Increase  Decrease 
 
Recruitment 
chemotaxis 
adhesion 
 
M2 phenotype 
activation 
VEGF secretion 
EC tube formation 
NFĸB activation 
Arginase1expression/act
ivity 
 
Survival 
apoptosis 
 
 
 
- 
+ 
 
 
+ 
+ 
+ 
+ 
 
 
+ 
 
 
+ 
- 
 
 
- 
- 
- 
- 
 
 
- 
 
 
TNFR1/2 
unknown 
 
 
MCSF 
MCSF 
 
unknown 
 
 
unknown 
A + denote in the increase column or the decrease column indicates whether the molecule 
increased or decreased a macrophage function, respectively. – denotes an opposite effect 
was observed. 
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TABLE 5.2. Cells used to investigate breast cancer cell / stromal cell interactions 
 
 
Cell line 
 
NMuMG 
67NR 
4T07 
4T1 
 
J774 
RAW 
D1 
2H11 
 
Origin 
 
epithelial 
epithelial 
epithelial 
epithelial 
 
monocyte 
monocyte 
mesenchymal 
endothelial 
Cancer Stage (if applicable) Source 
 
ATCC* 
Dr. F. Miller** 
Dr. F. Miller 
ATCC 
 
ATCC 
ATCC 
ATCC 
ATCC 
Benign 
- 
+ 
 
 
 
NA 
NA 
NA 
NA 
Invasive 
- 
- 
+ 
 
 
Metastatic 
- 
- 
- 
+ 
* http://www.atcc.org/ 
** Generously given by Dr. Miller (Karmanos Cancer Institute, Detroit, MI- 
http://www.karmanos.org/) 
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